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Introduction: Since the introduction of anti-retroviral therapy (ART), treatment initiation
criteria have continually been revised to start these lifesaving drugs before onset of advanced
disease and optimize ART benefits for people living with HIV. However, little is known about
the effect of these changes on treatment outcomes among young people. We evaluated the
effect of such a policy change on long term adherence and treatment outcomes among young
people, aged 15-24 years.
Methods: We conducted a retrospective cohort analysis of young people, 15-24years old,
who started ART from January 2012 – December 2016. We used administrative data from the
District Health Information System (DHIS2) and the national referral hospital’s EMR. We
compared young people who started ART in the period July 1st, 2014 to December 31st, 2016
to a historical cohort that was treated in January 1st, 2012 to 30th June 2014 before the policy
change. Multivariable logistic regression was used to assess the effect of the 2014 policy

change on ART adherence and opportunistic infections among those who started treatment
before and after the guidelines changed. We also run a Cox Proportional Hazards regression
to examine the effect of the policy change on survival.
Results: On average, the health facility providing ART and having an opportunistic infection
at the start of ART, had an effect on ART adherence. The policy change did not have an effect
on ART adherence. Young people who started ART after the policy change had lesser odds of
having an OI compared to those who started ART before the policy at 3, 6 and 12 months on
ART. Age, the health facility, weight, and WHO disease stage were also associated with having
OIs, as well as duration in pre-ART care, ARV regimen and number of pills per day. There was
no significant difference in the survival probabilities and the hazard ratios of young people
who started ART before and those who started ART after the policy changed. Also, WHO
disease stage, weight at ART start and ART adherence at the time of death had an effect on
survival.
Conclusion: This study found that ART adherence among young people was mainly driven by
differences between health facilities providing ART in Uganda and whether an individual had
an OI at ART start and not by policy change. Furthermore, early ART initiation reduced the
risk of OIs among this population. Young people who initiated ART after the policy change
were less likely to have an OI after starting treatment. Young people were also more likely to
survive longer after ART initiation regardless of whether they started ART before or after the
policy change.
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INTRODUCTION
Although the current decade has seen an increase in the number of people on life saving
antiretroviral medication, the Human Immunodeficiency Virus (HIV) continues to be a public
health threat. Antiretroviral therapy (ART) has reduced morbidity and mortality among people
living with virus with more than 11 million lives saved globally in the last decade. Efforts have
therefore been made to maximize the benefits of antiretroviral therapy (ART) initiation by
starting treatment as soon as one is diagnosed with the virus, at higher CD4 thresholds and using
once-a-day fixed-dose combination regimen. However, the success of ART depends on sustaining
high levels of ART adherence for viral suppression to stall disease progression.
In Uganda, a high prevalence rate, an increase in number of children who were perinatally
infected with HIV becoming adolescents and adults, and an increase in new infections among
young people, is a growing concern for health professionals and policy makers. Despite increased
ART coverage, the threat posed by a higher treatment burden, documented poor adherence,
increasing infections and mortality rates that are not decreasing as in other age groups in this
population, cannot be overlooked. In addition, little is known about the impact of the changes in
ART guidelines on ART adherence and treatment outcomes in this population. We therefore
sought to evaluate the effect of the 2014 ART policy on ART adherence, opportunistic infections,
and survival among young people, aged 15-24 years and provide information that can be used to
improve HIV interventions.

1

BACKGROUND
Uganda has a population of close to 35 million people, 23% of whom are between 18-30
years and more than 55% are children below 18 years1 . Despite a decline from 18% in the early
1990s to 7.3% in 2010, Uganda still has a high HIV-related disease burden with a prevalence rate
of 6.0% for the general population and nearly 4% among adolescents and young adults 15-24
years1,2 . Findings from the 2016 Uganda Population HIV Impact Assessment reported a gender
disparity in the HIV prevalence among young people aged 15-24 year with females
disproportionately affected at 3.3% compared to 0.8% among males2,3. Of the estimated 1.4
million people living with HIV, only about 30% of eligible adults and 47% of eligible children
received antiretroviral (ARV) drugs. In 2016, only 27% of adolescents and young adults who were
eligible for ART were started on treatment3. A recent worrying trend is the rise in new infections
among this age group, with young women being disproportionately affected. An average of
22,000 new HIV infections among 15-24-year olds, were reported in 2016 4 of which 68% were
young women 15-24 years. AIDS-related mortality is still high and opportunistic infections (OI)
are still a major cause of death among those whose treatment is not keeping their HIV levels low
enough for their immune system to fight off infections. All these problems can be linked to
suboptimal ART adherence as has been widely reported in the literature which increases the risk
of poor treatment outcomes.
HIV is an infection that compromises the immune system leaving the infected person
susceptible to opportunistic infections, leading to high morbidity and mortality. There is no cure
2

for HIV. However, the use of a combination of three or more antiretroviral (ARV) drugs, herein
referred to as antiretroviral therapy (ART) suppresses the virus from replicating. This suppresses
disease progression and prolongs the life of the person living with HIV (PLWH). Viral suppression
is still a challenge given that poor ART adherence still persists among PLWH.

Antiretroviral Treatment Guidelines
In Uganda ART is implemented under the WHO guidelines that have been disseminated
since 2002. Revisions have been made over the years as new advances in treatment and new
data become available. In 2013, WHO provided updated and consolidated guidelines
recommending earlier ART initiation at a higher CD4 cell count threshold, after findings from 3
randomized clinical trials and 21 observational studies demonstrated better clinical outcomes for
patients who started ART earlier compared to those for whom ART was delayed 5. Therefore, all
adults and adolescents started ART at CD4 cell count ≤ 500cells/mm3, using a more efficacious
first line regimen with less life-threatening side effects. Priority was given to those with advanced
disease or with CD4 cell count ≤ 350cells/mm3. A 2nd edition of the consolidated guidelines was
disseminated in 2016 but for this study the focus is on the 2013 ART guidelines (implemented in
Uganda in July 2014) because we believe that information has implications for the latest
guidelines.

3

Healthcare System and HIV service provision
In Uganda, the majority of healthcare is provided by the government through a tiered
system comprising of the National Referral Hospitals (NRH), Regional referral hospitals (RRH),
General hospitals, lower-level health centers (Level IV- Level II) and village health teams (VHT).
The RRHs are located in each of the 14 health zones that cover the four geographical regions of
the country, within 5 kilometers of the majority of the population. These provide the bulk of HIV
treatment services in the country. HIV care and treatment though provided at all levels of the
healthcare delivery system, most of the financial support is from international donors like the
Centers for Diseases Control and Prevention (CDC), The Joint United Nations Programme on HIV
and AIDS (UNAIDS), and The United States Agency for International Development (USAID). These
work in collaboration with the Ministry of Health, national implementing partners like BaylorUganda and the existing health facilities.

HIV Treatment and Follow-up
Patients who are diagnosed with HIV are referred to the HIV clinic for care and treatment.
Those who are eligible for ART receive at least 3 counselling sessions, in accordance with the
national treatment guidelines to prepare them to start ART which is a lifelong commitment. The
first follow-up visit is scheduled 2 weeks after ART initiation to monitor response to the
prescribed regimen including drug toxicity and side-effects. Thereafter monthly visits are
scheduled. Patients that are stable are given longer (usually 2 months) appointment times, which
4

is unusual for adolescents and young adults because of their challenges with adherence. The
clinic visits are scheduled to coincide with the ARV drugs refills. During each visit, patients
undergo a comprehensive clinical assessment that includes a physical examination and virological
testing as described in the national guidelines. The parameters assessed included ARV drug
regimen and adherence to medication; potential side effects; weight and height; TB status and
presence of other OIs; loss of function; clinical disease stage; laboratory investigations and
whether the patient had been hospitalized since the last clinic visit. CD4 count tests are done
every six months and viral load testing is done 6 months after initiating treatment and annually
thereafter. Patient records are routinely updated at every clinic visit including those that are lostto-follow-up (LTFU), transferred in from other clinics/out to other clinics, or have died. Most
deaths are reported by relatives, community health workers and volunteers. Since there is no
death registry, for this study, we used the recorded date of death in the medical record.

Antiretroviral Therapy before and after July 2014
Prior to July 2014, ART initiation was recommended for PLWH with a CD4 cell count ≤350
cells/mm3 or with advanced disease stage 3 or 4 as defined in the World Health Organization
Clinical staging guidelines. This is referred to as “delayed ART” because the patient started ART
at a certain level of disease severity (WHO guidelines). A patient with a higher CD4 count was
more likely to be Stage I or II and was considered to be healthy and therefore did not need ART.
However, a patient with a lower CD4 count was more likely to be Stage III and IV and therefore
5

needed ART to stop the disease progression. In resource-limited settings where CD4 testing was
not widely available, clinical disease stage was the criteria used to initiate ART. Also, before 2014,
priority for ART was given to children <5 years, pregnant women and very sick PLWH. Therefore,
during this period, many young people did not start ART if they did not meet the eligibility criteria.
Their ART was delayed in this context. Patients with WHO clinical stage I or II were given
cotrimoxazole prophylaxis to reduce the risk of opportunistic infections and given medication for
any other problems they had. All patients were assessed physically and immunologically on a
monthly basis for signs of disease progression. In July 2014, Uganda adopted and implemented
the 2013 WHO ART guidelines which recommended that ART be initiated for PLWH at CD4 cell
count ≤500 cells/mm3, referred to as “early ART initiation” because a higher CD4 count is
indicative of a healthier person. This led to more PLWH started ART before getting to the
advanced disease stages.
ART initiation in both time periods (pre- and post-July 2014) was administered using one
non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside reverse transcriptase
inhibitors (NRTIs), as first line therapy. The NNRTIs included Efavirenz (EFV) or Nevirapine (NVP).
The NRTIs were Zidovudine (AZT), Tenofovir (TDF), Lamivudine (3TC) or Emtricitabine (FTC).
However, whereas pre-July 2014 the patients could be started on either AZT or TDF, post-July
2014 all patients had to be started on a TDF-based regimen, with Efavirenz (EFV) as the preferred
option for the NNRTI. The ARV drugs are administered as a triple fixed dose combination, for
example, TDF/3TC/EFV or as duo fixed dose e.g. TDF/3TC used with another separate ARV such
6

as EFV or NVP. The choice of regimen was guided by the patient’s clinical condition, availability
of drugs and presence of a contra-indication to any of the available drug options.

Study Sites
The research study was conducted in four tertiary level hospitals; one national and three
regional referral hospitals, selected for their geographical representation. Each of these hospitals
has a specialized HIV clinic for young people that is open all week days. Patients routinely receive
a package of services that includes adherence assessment and support education and counseling,
and clinical and laboratory monitoring for disease progression and opportunistic infections. A
peer model in which young people are trained to identify fellow young people with adherence
challenges and support them is used to foster adherence. Patients with poor adherence are each
initiated on an intensive adherence counselling plan and followed up till they reach satisfactory
levels before being reintegrated into routine clinical routines. Across all the four sites, ART and
other forms of HIV treatment is free of charge with a centrally procurement and distribution
system run by government warehouses. With the exception of the national referral hospital that
has a computerized physician order entry system, regional referral hospital operates a paper
based clinical notes system in which clinical findings and treatment procedures are summarized
on a patient card during each follow up visit. These cards are kept at the health facility and later
entered an EMR data base (District health information system [DHIS2]) for analysis and reporting.

7

Baylor College of Medicine Children’s Foundation-Uganda (Baylor-Uganda)
Baylor-Uganda is located in Mulago National Referral Hospital in the central region, and
also serves as a teaching hospital for medical professionals. An affiliate of the Baylor International
Pediatric AIDS Initiative (BIPAI)’s network of clinics, Baylor-Uganda is the largest pediatric HIV
clinic in Uganda and Africa that provides comprehensive HIV care and treatment services for
children and adolescents infected with HIV/AIDS. The clinic has been in existence since 2003 and
has an estimated daily attendance of about 200 patients with a total enrollment of 7000 patients.
Over 1800 patients aged 15-24 years have been started on ART since 2011.
Fort Portal Regional Referral Hospital
The Fort Portal Regional Referral Hospital, located in Western Uganda, serves close to
500,000 people in the Rwenzori Region. The HIV clinic, founded in 2002 has a total enrollment of
nearly 8000 patients in care with about 7000 started on ART between 2011 to date.
Mbale Regional Referral Hospital
The Mbale Regional Referral Hospital is located in Eastern Uganda. A cumulative total of
about 6400 adults and children are currently receiving ART at the hospital’s HIV clinic. Of these
400 adolescents and young adults have started ART since 2011.
Gulu Regional Referral Hospital
The Gulu Regional Referral Hospital, located in the northern region, offers comprehensive
HIV services to the Acholi sub-region. Over 6000 patients with HIV infection are receiving ART at
the HIV clinic, 786 of whom are adolescents and young adults.
8

STATEMENT OF THE PROBLEM
Although HIV infections have reduced tremendously in the last few decades, Uganda still
has a high HIV-related disease burden with a prevalence rate of nearly 4% for young people, 1524 years3 . The number of children who were prenatally infected with HIV, who are surviving into
adulthood is increasing. The rise in new infections and AIDS-related deaths among this age group
is also a source of concern among health professionals and policy makers. The initiation of ART
at a higher CD4 count threshold herein referred to as “Early ART”, using more efficacious ARVs
and a lower pill burden, it is believed will greatly reduce the number of infections and deaths 3-8.
However, the success of ART relies on sustaining high levels of ART adherence for viral
suppression9,10, which is a problem in this age group.
Early ART initiation also raises medication adherence concerns in a population that has
been widely reported to have poor adherence11-15. The threat of poor adherence in this age group
cannot be overlooked given that ART adherence rates are lower, mortality rates are not
decreasing as in other age groups and there is a rise in new infections8,16. Between 2005 and
2012, the number of deaths among this age group increased by 50% whereas overall it had
decreased by 30% 6. In Uganda, a total of 5200 AIDS-related deaths were reported among young
people 15-24 years in 20164. The risk of drug resistance is increasing and this has implications on
viral suppression. Young people are staying on treatment longer than adults leading to a higher
treatment burden, it is therefore important to examine the implications of these policy changes
on treatment outcomes.
9

Furthermore, most published literature focusses on children and adults, is mostly from
high income countries, with this age-group aggregated as either children or adults, and therefore
excluded in most of the statistical data analyses. More studies with better age disaggregation are
needed.
Although a few studies have examined the effect of treatment guidelines in sub-Saharan
Africa and Uganda, their main focus was drug efficacy, reducing morbidity and mortality. None
of these studies have assessed the effect of the changing ART guidelines on adherence and
treatment outcomes in this age group and the implications on future HIV programs. Therefore,
in this study, we sought to assess the effect of changes in ART guidelines on ART adherence,
opportunistic infections and survival among young people in Uganda, 15-24 years, who initiated
ART before and after the implementation of the 2013 ART guidelines.
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LITERATURE REVIEW
A considerable amount of literature has been published on treatment outcomes since the
outbreak of the HIV epidemic. However, the limitations of current studies on adolescents and
young adults, not limited to study designs, study populations, and mixed results underpinned the
importance of this study. The benefits of ART on outcomes for people infected with HIV cannot
be over emphasized and a substantial amount of literature has been published about it.
However, only a few studies have been done in resource-limited settings like Uganda. There is
even more paucity of information when it comes to adolescents and young adults.
A substantial amount of literature available for Sub-Saharan Africa is based on pre-2010
ART treatment guidelines that recommended ART initiation at a lower CD4 count threshold
(<200cells/mm3) and the available ARVs were less efficacious than those currently available. ART
initiation is currently recommended at a higher CD4 count threshold (≤ 500cells/mm3), using
more potent ART regimens5,7. For this study, we sought to understand how newer (2013)
guidelines impacted treatment outcomes in Uganda. We analyzed data from adolescents and
young adults over time and believe that the results can be used to inform policy and improve
effectiveness of ART among this population.
Early initiation of ART is associated with reduced mortality and morbidity caused by the
HIV infection. Montaner et al. (2014) who sought to characterize the association of HAART with
new AIDS cases and mortality, reported an 80% reduction in both AIDS incidence (from 6.9 to 1.4
per 100,000 population) and HIV-related mortality (from 6.5 to 1.3 per 100,000 population)8.
11

Positive results have also been reported elsewhere. A multi-country study of 30 countries with
the highest AIDS mortality burden found that access to ART averted about 1,051,354 and 422,448
deaths in South Africa and Nigeria and increasing coverage could avert 2.2 and 1.2 million deaths
respectively 9,10.

ART among Adolescents and Young Adults
Considerable evidence shows that successful treatment of perinatally infected children, in
addition to managing opportunistic infections and increasing ART coverage has led to an increase
in the number of HIV-infected adolescents and young adults on ART17,18 . Nachega et al. (2009)
argued however, that despite the number of large studies that described virological outcomes of
ART in adults and children, very few looked at adolescents and young adults per se. For example,
the START Trial11 that assessed the clinical outcomes of immediate versus delayed ART initiation
did not include adolescents.
Adolescents are at risk of poor health outcomes and acquisition of new HIV infections as a
result of poor use of ART. Mutevedzi and Newell (2014) reported a large number of new HIV
infections showing up among adolescents and young adults. Data from the Global Health
Observatory Data Repository supports this finding. Furthermore, adolescents have poor
adherence rates compared to adults and children12.
“Over one third (38%) of adolescents globally are sub-optimally adherent to ART, with
substantial regional variation”13 .
12

“HIV infected adolescents and young adults on ART in Southern Africa have poor
adherence rates and poor virologic outcomes than their adult counterparts”14.
A review by Lowenthal et al. (2014) of the changing epidemiology of HIV among
perinatally-infected adolescents in Sub-Saharan Africa also revealed increased risk of chronic lung
disease, cardiac disease, skin, renal and bone disease. They also noted that growth failure was
more pronounced during adolescence. All this affected adherence to treatment, education and
the overall quality of life. They further argued that existing studies were cross-sectional in nature,
had small sample sizes and lacked controls against which comparisons could be made. On the
other hand, studies from high income settings lacked age-specific data. These mentioned
limitations made generalizability of the results to HIV-infected adolescents and young adults in
Uganda a challenge.
Ford, Mills and Egger (2014) in their editorial commentary argued that the meta-analyses
such as the one done by Siedner et al. (2015), were prone to ecological biases because of the use
of aggregated data. Similar studies like Ferrand et al. (2016) scored the quality of many of the
studies used in their systematic review as low or moderate. They could not make accurate
estimates about the effectiveness of ART on viral suppression because there was a lot of variation
in the number of adolescents achieving viral suppression in the studies they reviewed. They also
found that many of the studies did not stratify by duration of ART and none included age-specific
analysis both of which were associated with treatment adherence. This was a gap that this study
hoped to address.
13

It should also be noted that before 2010, only children 0-5 years were started on ART if
they tested positive for HIV. Older children, adolescents and adults, started ART only if they had
advanced disease, defined by the WHO as clinical disease stage III and IV or having a CD4 cell
count below a recommended threshold. Therefore, newly diagnosed adolescents and young
adults may not have been eligible for ART and thus were excluded from most studies. According
to UNAIDS, in 2013 there were 200,000 young people (15-24 years) out of 1.2million PLWHA in
Uganda. Of these 41% adults (15+years) were started on treatment. The number of young people
15-24 years is not disaggregated. This study sought to capture more of them and provide results
that are more generalizable.

Adherence to ART
Early ART does not only have implications on costs, service delivery and access to care, but
also on adherence. As earlier mentioned, long-term medication adherence is a challenge for any
disease and HIV is not an exception. Added to this is the frequently required clinic visits which is
still the case in Uganda as in many other Sub-Saharan African countries. Recent studies15,16 in
the US that underscored the importance of timely and uninterrupted care, also reported a high
rate of missed clinic visits during the first year in HIV care. Furthermore, social and psychological
factors, adverse side effects, drug toxicities, pill burden, daily doses and drug interactions are
documented barriers to ART adherence. Although the current ARV drugs are more potent and
effective17, they still have minor adverse effects that PLWHA have to deal with.
14

Medication adherence is a major determinant of ART success. Several studies 13,18,19 found
that non-adherence to ART treatment led to drug resistance, increased viral load, disease
progression, decreased CD4 cell count and death. It was also argued that not all PLWHA took
their medication as prescribed. Different approaches such as clinician documented prescription
refills, directly observed therapy, self-report and microelectromechanical systems (MEMS)
technology have been used to address this problem. However, non-adherence remains a major
threat to the success of ART.
A meta-analysis by Stricker et al. (2014) found that on average 62% of patients reported ≥
90% adherence. These findings are similar to those reported in an earlier study by Mills et al.
(2006)20. However, a retrospective study done in Nigeria19 that analyzed medication refill
adherence found that refill adherence reduced with successive visits. This means that fatigue set
in, which in turn affected adherence overtime. Even with the single once-daily fixed dose
regimen that has reduced the pill burden tremendously, Gulick (2010)21 found that only 60-80%
of patients achieved complete viral suppression.
Concerning adolescents and young adults many study findings pointed to their poor
adherence compared to children and adults. Findings from a systematic review by Kim, Gerver,
Fidler and Ward (2014) found that almost 40% of adolescents who were eligible for or started
ART were non-adherent to treatment. Nevertheless, they also noted that the studies in that
analysis looked at the period before the CD4 count threshold for ART initiation was raised, the
ART regimens were less potent and had unpleasant side effects. Therefore, analyses that are
15

more recent were needed to assess adherence among this population. They also noted
considerable variation in the studies that were included in the review most of which were crosssectional because the paucity of longitudinal studies. Also, countries like the United States, Brazil
and South Africa were over-represented. Existing data is therefore incomplete and the
magnitude of the problem of non-adherence is not really known. It is also likely that the incidence
of medication non-adherence is actually higher than published. The methodological difficulties
associated with measuring adherence may therefore be underestimating the extent of the
problem.
In Uganda adherence is measured using pill counts and self-reports. At each clinic visit, the
patient is asked to return with all medicine containers from the previous visit and a pill count is
done and recorded in the patient HIV care/ART card. This card is a record of all patient
information, including all follow-up visits and is kept at the health facility/clinic. Clinic visit
reminders, and other information is recorded in the patient’s book that acts as a copy of the
patient’s medical record that the patient has access to. However, research has shown that pill
counts and self-reports are subjective and may be over reporting adherence and underestimating
the problem of non-adherence. This may be associated with the increase in AIDS-related
mortality, likelihood of OIs and new HIV infections among this population.
Furthermore, many factors affect adherence in this age group. Social and psychological
factors22, treatment fatigue12, stigma and size of tablets23, education24 and transitioning from
pediatric care to adultcare25, and non-disclosure20 have been documented in published
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literature. The association between age and adherence has already been established. Adherence
is reported to decline with age among adolescents and young adults26. The Pediatric AIDS Clinical
Trial Group (PACTG 219C) found 76% adherence rates for ages 15-18 years compared to 83-89%
in younger children26. Mekuria L.A et al. (2017), Auld et al. 2014 and Nachega et al. (2009) also
found significant associations between age and suboptimal adherence.
We cannot overemphasize the need for more evidence-based literature. Most of the
literature on ART adherence among adolescents and young adults is from high-income countries.
The meta-analysis by Mills et al. (2006) that is cited in most literature did not include adolescent
populations from Africa. Furthermore, very few longitudinal studies have been done in SubSaharan Africa. One longitudinal study done by Sasaki et al. (2012) in Zambia focused on a ruralbased population sample using pre-2010 ART treatment guidelines. Current analyses, like this
study, are therefore needed to assess factors associated with ART adherence and allow for more
generalizable results.

Opportunistic infections (OI)
OIs are still a major threat to PLWHAs as they increase the risk of morbidity and mortality1922

. They negatively affect the quality of life and threaten the success of ART treatment. Findings

from Rubaihayo et al. (2016) showed that OIs increased stigma, affected a patient’s response to
treatment and led to increased healthcare costs since the affected patient had to visit the health
facility more frequently.
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ART reduces the load of HIV in an infected person’s body enhancing the person’s ability to
fight off OIs and live longer. A large cohort study by Guillen et al. (2010) reported that ART
initiation led to a reduction in incidence and prevalence of OIs among children in high-income
countries. In 2016, a systematic review by Drouin et al. (2016) focused on low- and middleincome countries (LMIC), found similar results except for bacterial pneumonia, tuberculosis (TB),
and candidiasis. They however noted that many of the studies lacked lost-to- follow-up data that
was key in incidence studies. They also lacked data on confounders such as CD4 cell count, age
at ART initiation and use of cotrimoxazole prophylaxis, a key medication used to prevent OIs.
Poor adherence, a major determinant of treatment failure increases the risk for OIs27.
Iroezindu and colleagues (2013) examined the OI prevalence and risk factors in patients on ART.
They found that 22.4% had OIs despite reported good adherence rates among 78% of study
participants. The study may have under- or over-estimated some infections because it lacked
diagnostic test data.
Although the evidence supporting the success of ART in significantly reducing OIs and AIDS
progression cannot be disputed, differences still exist in the burden of OIs between high-income
countries (HIC) and LMIC settings. Prevalence and incidence rates also vary between and within
countries - 22.4% was reported by one study in Nigeria28, 30% in Senegal29, and 47.6% in South
Africa30. Studies done in Ethiopia31 and West Africa32 had similar findings. The endemicity of
diseases such as tuberculosis and pneumonia in some areas may have influenced study findings.
However, different CD4 count thresholds were used in each of these studies and that variation
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should be accounted for when using the results. A systematic review by Low et al. (2014) that
reviewed studies from Sub-Saharan Africa, Asia, Latin America and the Caribbean noted a 57% 91% decline in risk of oral candidiasis, toxoplasmosis and Pneumocystis pneumonia (PCP), during
the first year on ART. They still found a significant number of PLWHA presenting with advanced
disease, an issue that cannot be overlooked in face all the achievements made by ART. However,
they also noted that there was a lot of variability in study parameters such as reporting
cotrimoxazole prophylaxis, ART regimens, and duration on ART, follow-up times and lack of
information on important confounders like CD4 cell count.
As earlier noted, adolescents and young adults have been understudied. Most of the
literature focuses on adults and children. According to Shroufi et al. (2013), many research
programs put little emphasis on adolescents and young adults and concentrated more on infants
and younger children. With reported poor adherence to ART, the risk of OIs among this subgroup
is increased but it is not documented. An observational cohort study by Nachega et al. (2009)
found that lower virologic suppression and immunologic recovery was common among
adolescents and young adults because of poor ART adherence. This increases the risk of
infections.
A few of the studies done in Uganda focused on children ≤ 15 years but with more
emphasis on infants. Others focused on adults 18 years and above. Literature on adolescents and
young adults is very limited. A prospective cohort study by Namutebi, Kamya and Byakika-Kibwika
(2013) focused on the age group 28-40 years and found that though OIs had declined, they should
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not be ignored because patients still present with advanced disease. Rubaihayo et al. (2016)
assessed OIs before and after ART initiation and found that OIs accounted for 91% of all
opportunistic events, the most common being diarrhea < I month and geohelminths. They also
found that oral candidiasis was still present although not as highly prevalent as in previous years.
These studies, however, used different study designs, had adults as their study population, and
some lacked data on confounders like patient’s CD4 counts, duration on ART and reported ART
adherence.
It was therefore important to obtain updated analyses on the impact of ART on OIs, ever
since the global scale-up of ART coverage and use of more potent ART regimens. Existing
literature such as Holmes et al. (2003), Nachega et al (2009), and Hull, Phillips and Montaner
(2008) preceded this period and/or addressed specific OIs and regions. Low et al. (2014) also
argued that country-specific evidence-based assessment of prevalent OIs would help define local
priorities and inform targeted expenditure on and procurement of relevant prophylaxis drugs, in
addition to treatment of HIV-related comorbidities.
This longitudinal study sought to provide updated information by exploring the magnitude
of OIs among young people in Uganda and identify the risk factors associated with them.

Survival and Predictors of Survival
The use of ART has been associated with improved survival among PLWH. It is one of the
indicators, though difficult to measure, that is used to evaluate program performance. One of
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the causes of death among PLWH is the presence of OIs. Patients with advanced HIV disease
have a higher risk of OIs when initiated on ART, which in turn increases their risk of death. Results
from a South African study showed that OIs and the Immune Reconstitution Inflammatory
Syndrome (IRIS) were major causes of death after initiation of ART33. IRIS is a combination of
clinical signs and symptoms considered to be associated with immune recovery brought about
by a response to ART. It occurs among 10–30% of the people initiating ART, usually within the
first 4–8 weeks after initiating therapy.
Furthermore, patients with poor adherence have a higher risk of death because of poorly
controlled viral load. Ayele, Mulugeta, Desta and Rabito (2015) found that the risk of death was
nearly 3 times higher (HR: 2.9695, 95% CI: 1.396 – 5.203) among patients with poor adherence
compared to those with good adherence. A similar study in Ethiopia by Hambisa, Ali and Dessie
(2013) found that non-adherent patients were 27 (95% CI: 8.928, 86.8) times more likely to die
than adherent patients were. However, the confidence interval was wide. A Ugandan study34
reported that non-adherent patients were 2 times more likely to die compared to adherent
patients. But as noted with many studies, the study by Hambisa et al. (2013) had a lot of missing
data on OIs, an important determinant of mortality used in several studies.
According to the WHO and UNAIDS, adherence to ART is critical to the survival of PLWHA
since poor adherence was the main reason for poor treatment outcomes35.Early initiation of ART
improves survival of PLWHA7,23,24 and reduces the cost of healthcare. Cost-effectiveness studies
such as Bendavid, Grant, Talbot, Owens and Zolopa (2011) found that a TDF regimen was
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associated with highest survival (135.2 months of quality adjusted life expectancy), and fewer
opportunistic infections 36.
Despite the benefits of ART in improving survival, patients still die when started on ART
although the numbers as not as high as they used to be. The number of patients that died in the
first year of ART was estimated to be between 8% - 26%37. Most of the deaths occurred in the
first few months of ART. This may change as more updated analyses based on newer ART
guidelines recommending earlier ART initiation at a higher CD4 count threshold and with more
potent ARVs, become available. Amanzi, Michelo, Simoonga, Dambe and Chongwe (2016)
reported low survival rates during the first year on ART, similar to findings from Tanzania38 and
Cameroun39. A patient with a lower CD4 count (≤200 cells/mm3) had a lower chance of survival
compared to one with a higher CD4 count (≤350 cells/mm3) at the start of ART. The median
survival found in a 5-year Tanzanian cohort was 24 months40. This was lower than was reported
in an earlier Tanzanian cohort by Johannessen et al. (2008) and in Uganda 34. The Cameroun
study39 also found patient characteristics, adherence and quality of healthcare were independent
predictors of survival.
A 2015 retrospective cohort study done in Ethiopia found that 12.2% of the patients died
during 5 years of follow-up, 68% of whom died in the first 6 months of ART initiation 41. Mageda,
Leyna and Mmbaga (2012) found that mortality was 4.3 per 100-person years with more deaths
happening within the first 5 months following ART initiation. The authors noted however, that
most patients had CD4 cell count less than 200 cells/mm3. This variability could be explained by
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the different time-periods, wide variation in age-range and different study designs, in addition to
the low CD4 count. It should also be noted that highly active antiretroviral therapy (HAART) was
not readily available in many African countries before 2012. Therefore, current analyses will
significantly contribute to the body of knowledge since they are based on a higher CD4 cell count
and more potent ARVs that are now available.
One can also argue that although Nachega et al. 2009 is one of the very few published
studies reporting adolescent clinical outcomes in Africa, the causes of mortality among
adolescents and young people was not well documented. This supports the argument that
adolescents and young adults living with HIV have been understudied and yet available literature
highlights their risk of poor health outcomes. This study sought to add to available research by
providing adolescent and young adult-specific data that can be used to improve HIV interventions
in this population.

Patient Factors
Uganda scaled up efforts to increase ART coverage countrywide in 2012 and with the
reported success, it is easy to overlook what is happening over time. Studies also demonstrate
that ART alone is not a sole determinant of mortality.
A patient’s use of healthcare services is a function of predisposing, enabling, and need
factors as demonstrated by the Andersen Behavioral Model. A substantial amount of studies
found associations between these factors and ART use. Greer et al. (2015) examined the
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association between new HIV patients and IOM treatment indicators and found that poverty was
associated with poor adherence to ART and poor clinic appointment attendance. Age was also
found to be significantly associated with ART use26.
Furthermore, if patients are not ready to start ART, treatment initiation would be delayed,
which in turn increased the risk of transmission, disease progression and even death. This is a
serious concern for both patients and health providers. Many of the patients perceive ART as a
death sentence25,26 . Therefore, preparation and assessment of the patient’s readiness has to be
taken into consideration too.
This study sought to provide a deeper understanding of factors, specific to Uganda, that
affect adherence to HAART among adolescents and young people living with HIV, to better
develop interventions to improve adherence in this population and reduce barriers to HIV care
and treatment.
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PUBLIC HEALTH SIGNIFICANCE
The importance of documenting what happens to adolescents and young adults in order
to design interventions that will effectively improve HIV treatment outcomes cannot be
overlooked. The HIV epidemiology has changed and coupled with new antiretroviral treatments
and treatment indications, there is need for more timely data. This study provides countryspecific evidence-based assessment on occurrence of opportunistic infections, ART adherence
and survival among adolescents and young adults. This information can be used to identify
priority areas in HIV service provision and improve treatment outcomes especially as the country
seeks to implement the latest guidelines aimed at further reducing the time between HIV
diagnosis and ART initiation. This longitudinal analysis also provides policy makers with a deeper
understanding of factors that are associated with early initiation of ART in this population. This
information can then be used to target expenditure on, and the procurement of relevant
prophylaxis drugs, in addition to treatment of HIV-related comorbidities. Furthermore, this study
will contribute to the growing body of research5, and in addition to ongoing trials to evaluate the
impact of early ART initiation, barriers and drivers of adherence, and incidence of adverse events
from increased exposure to ART. This study therefore provides updated information that can be
used to improve ART adherence and treatment outcomes among young people in Uganda and
thereby reduce barriers to HIV care and treatment.
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THE CONCEPTUAL FRAMEWORK
The conceptual framework that underpinned this study is a modified version using
features from both the Donabedian Structure-Process-Outcome (SPO) model42,43 and the
Anderson Behavioral model (ABM)44, underpinned by the HIV Care Continuum45,46. The SPO
model illustrates the relationship between structure, process and outcome of the healthcare
system, the ABM model incorporates the patient characteristics influencing that relationship.
The HIV Care Continuum (HCC) illustrates the stages of care a person living with HIV goes
through from diagnosis to viral suppression. It is used globally to track the number of PLWH at
each stage and identify priority areas to improve HIV delivery services. The stages, important in
the fight against HIV, involve having adequate care provision conditions and resources to provide
that care. On the other hand, however, the success of HIV care is also dependent on the patient’s
right and willingness to accept or defer treatment5. This is influenced by a number of factors
illustrated by the ABM model in the literature as predisposing, enabling and need factors. This
study focused on the predisposing factors of age and sex27,28, and examined their association with
the study outcomes. In the Donabedian model, structure is defined as “the conditions under
which care is provided, including material resources, human resources, and organizational
characteristics”42. In order to provide quality HIV treatment, adequate physical and human
resources have to be available. For this study we operationalized structure as type of health
facility, its location and patient volume. These were broadly defined since the detailed aspects
are not the focus of this study. The process of providing HIV care includes ART treatment routine
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clinic visits, drug refills and viral load monitoring, among other activities. Donabedian defined
these as the “set of activities that constitute health care, including diagnosis, treatment,
rehabilitation, prevention and patient education usually carried out by professional personnel”42.
If the process is not working well, then the outcomes would not be desirable. This study
operationalized the process as early initiation of ART for PLWH at CD4 cell count ≤500cells/mm3
as recommended in the 2013 WHO guidelines. We examined the association between early ART
initiation and study outcomes; (i) adherence to ART medication, (ii) occurrence of OIs and (iii)
survival, among adolescents and young adults living with HIV in Uganda. These outcomes were
defined to as “changes (desirable or undesirable) in individuals and populations that can be
attributed to health care”42. Figure 1 shows the modified model that guided this study. It
illustrates the relationship between the different components of this study.
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Figure 1: Conceptual Framework
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Hypothesis, Research Question and Specific Aims
Research Question
What is the effect of the changes in the WHO 2013 ART guidelines, herein referred to as early
ART initiation and adopted in Uganda in 2014, on treatment outcomes among young people living
with HIV in Uganda?
Overall Aim
The broad aim of this study was to assess the impact of changes in ART policies on patient
outcomes, over time, among young people living with HIV, 15 - 24 years of age, in high-volume
health facilities in Uganda. We hypothesized that young people who started ART after the policy
changes were implemented would have better treatment outcomes compared to those who
started ART before the policy changed.
Specific Aims
Aim 1: To assess the effect of changes in ART guidelines on ART adherence among young people
15 - 24 years, before and after the ART policy change.
Hypothesis: We hypothesized that young people would have better ART adherence after
the policy change.
Aim 2: To assess the effect of changes in ART guidelines on Opportunistic Infections (OI) among
young people 15 - 24 years, before and after the ART policy change.
Hypothesis: We hypothesized that there would be fewer OIs among young people who
initiated ART after the policy changed compared to those who initiated ART before.
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Aim 3: To assess the effect of changes in ART guidelines on survival and identify predictors of
survival among Young people 15 - 24 years, the ART policy change.
Hypothesis: We hypothesized that young people who initiated ART after the policy
changed would have a lower risk of death compared to those who initiated ART before
the policy change.
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METHODS
Study Design and Data source
We conducted a retrospective cohort study comparing young people who started ART in
the period July 1st, 2014 to December 31st, 2016 to a historical cohort that was treated in January
1st, 2012 to 30th June 2014 before the policy change. We used administrative data from the
District Health Information System (DHIS2) and the national referral hospital’s EMR. This data,
routinely collected from patients who receive HIV treatment at the health facilities during clinic
visits, is used to plan and track a patient’s treatment from the date of HIV diagnosis to the date
he/she leaves the clinic either through transfer-out to another clinic, lost to follow-up (LTFU) or
death.
For this study design we needed patient information over a period of time, which
information was not readily available in most health facilities. This study was conducted in four
tertiary level hospitals; one national and three regional referral hospitals, selected for their
geographical representation. These hospitals have a high patient volume, have electronic
medical records that covered the study period and therefore, provided an adequate sample
population. These health facilities were also at the forefront of implementing the new ART
guidelines before scale-up of services to lower-level health facilities.
Electronic Medical Records (EMR)
We used de-identified secondary data that was routinely collected from patients that
received HIV treatment and recorded in the EMR. The Baylor-Uganda EMR was developed by
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BIPAI in 2005 to manage real time registration, appointments and enhance tracking of patients.
It is used in all BIPAI-affiliated COEs in more than 10 different countries worldwide.
The Regional Referral Hospitals (RRHs) started using EMRs in 2011 using an open source
medical records system platform, OpenMRS which was developed for use in developing
countries. The OpenMRS system, a collaboration between the Regenstrief Institute, a worldrenowned medical informatics research institute, and Partners in Health a Boston-based
organization, focused on health service delivery for the underprivileged worldwide. This was later
revised and a newer platform, the District health information system [DHIS2]) was adopted at
the national level for reporting and analysis. The databases contain information on patient
demographics and clinical parameters, not limited to: date of diagnosis, ART initiation date, CD4
cell count, adherence, and presence/absence of OIs, stage of disease; registration date; and
status of the patient.
These databases were appropriate for this longitudinal study design because of the ability
to track a patient from the time of registration in the clinic, course of treatment, up till the time
they exited the clinic due to death, transferred-out to other clinics or are lost-to-follow-up. It was
therefore possible to follow-up the study participants over the study period.
Study Cohort
We defined the study population as young people aged 15-24 years. The study included
all HIV-infected young people, 15-24 years at the time of ART initiation, who started ART between
January 1, 2012 and December 31, 2016, regardless of the date of HIV diagnosis. We included
those who were newly diagnosed with HIV and those who were diagnosed prior to the study
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period but had not started ART. The cohort entry point was the date of ART initiation with each
study participant contributing follow-up time to the study period. Young people had to have data
for at least two follow-up visits, had to have started ART at the selected HIV clinics, and be on
lifelong ART. Young people who were LTFU or transfer-out during the study period were included
because they contributed time until the event happened. However, we excluded young people
who were lost- to- follow-up at the start of study period; started ART for Pre-exposure
prophylaxis (PrEP) because it is short term; had no records; and had started ART elsewhere
because the data from the original health facility was not readily available. The study cohort was
closed on December 31, 2017 to ensure that all study subjects had data for at least two followup visits.
For all the study participants that met the selection criteria, we extracted their pre-ART
data. The patient information included socio-demographic characteristics, date of ART initiation,
CD4 cell count, WHO clinical disease stage, cotrimoxazole prophylaxis, ARV regimen, number of
ARV pills given per day and ARV refills, among other patient data that was relevant to the study.

Sampling Frame
The sampling frame used for this study was the Pre-ART and ART registers in which all
patients diagnosed with HIV and received treatment at the selected health facilities are
registered. The registers contain both baseline and follow-up information about each patient
and are updated at every clinic visit.
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Sample Size
The selection of study participants was not based on probability sampling. We included
all patients that met the inclusion criteria in the analysis. However, we performed a power
analysis to obtain an adequate number of subjects to detect a difference and be able to answer
our research question. Literature on effect sizes used in HIV treatment outcomes research in
Uganda is very limited and mixed. However, a randomized clinical trial47 and case-control study48
conducted in Kenya used 10% effect size, the smallest difference that would be of clinical
importance in the HIV field. Results from meta-analyses (mean weighted ES) range from 0.10 –
0.7949,50,50,50,50,50,50,50,50,50,50,50,50. The total number of adolescents and young adults who were
included in the analysis was 3084. This gave the study 80% power to detect an effect size of 0.08
based on a two-sided t-test at 0.05 significance level, assuming that the outcome variable at
baseline was continuous and normally distributed.

Study Variables
Dependent Variables:
ART Adherence: The dependent variable “ART adherence” was defined as the percent
adherence for each patient during the first 12 months of starting ART. This was coded as a binary
variable, “1” if the patient had an adherence code corresponding to ≥95% adherence and “0”
otherwise. An adherence rate of ≥95% is the threshold necessary for sustained clinical
effectiveness of ART9,29,30. A young person was considered to be adherent if he/she had a code
of “1” for all the months at 3, 6 and 12 months of follow-up. An individual was considered to be
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less adherent if he/she had a code of “0” for any of the months at 3, 6 and 12 months of followup.
Opportunistic Infections (OI): We defined the dependent variable “opportunistic
infection” as a disease event diagnosed during a clinic visit and recorded in the patient’s medical
record as an OI. The ART clinics use the WHO classification of OIs5,31. This was coded as a binary
variable, “1” if the patient had an OI and “0” otherwise. A young person was considered to have
an OI if he/she had a code of “1” for any of the months at 3, 6 and 12 months of follow-up. An
individual who had an OI at 3 months, was considered to have an OI at 6 and 12 months.
Survival: We defined survival as the time between ART initiation and death or end of
study period. For more comparable results the total follow-up time for each group was restricted
to 36 months after starting ART. For young people in the pre-policy group, the censor date was
December 2014 and for those in the post-policy group, the censor date was June 2017. Length of
time was measured in months. The variable was coded as “1” if the patient died and “0”
otherwise.

Independent Variables:
Policy change group (pre/post): The independent variable of interest was a binary time
variable representing the before and after introduction of the guidelines (pre-policy=0, postpolicy=1). The pre-policy group included young people who started ART before July 2014 (January
2012 – June 2014) and the post-policy group included young people who started ART after July
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2014 (July 2014-December 2016). The ART start date was the date the patient was given a dose
of ARVs.

Socio-demographic variables
Age: Age is a key predictor of ART adherence. ART Adherence has been reported to
decline with age among young people32.
Gender: Studies have reported that females are more likely to be adherent to ART
compared to males. Females are disproportionately affected by HIV in this age group.
Health facility/ART clinic: The clinic providing the HIV treatment is important to this
analysis because of the geographical representation and the differences in structure and clinical
processes.

Clinical Characteristics
Weight: The weight of the patient is documented at each clinic visit so that any weight
loss in a short time is immediately addressed. Extreme weight loss is indicative of treatment
failure.
WHO clinical disease stage (coded as I, II, III and IV): The WHO clinical disease stage (I-IV)
is an indicator of disease severity and in the absence of CD4 testing and more recently viral load
testing, clinical stage was used as the eligibility criteria to assess for ART initiation.
CD4 count at ART start: CD4 count is a key indicator for both disease severity and
virological failure. It was commonly used during the study period to assess eligibility for ART. The
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change in ART policy raised the CD4 count threshold increasing the number of young people
starting ART.
Treatment Characteristics
Duration in pre-ART care (coded as 0, 1)
Pre-ART care is the time between a positive HIV diagnosis and ART initiation. This duration defers
from patient to patient depending on the health professional’s assessment of the patient’s
readiness to start ART and availability of drugs among other factors. One of the changes in the
guidelines has been the reduction of the pre-ART period.
ARV Drug regimen (coded as 0, 1)
This variable captured the ARV drug given to the patient at the start of ART. The regimen is not
changed unless the patient shows signs immunological or virological failure. Prior to 2014 a
patient could be started on either an AZT-based or a TDF-based regimen as first line. After 2014,
for all patients TDF was the first line regimen. It should be noted that those that were doing well
on other regimens prior to the change, were not switched to the new regimen. Among the ARV
regimens are TDF-3TC-EFV, TDF-FTC-EFV, TDF-3TC-NVP, TDF-FTC-NVP, AZT-3TC-EFV, AZT-3TCNVP, AZT-3TC-ATV, ABC-3TC-ATV, ABC-3TC-EFV, and other combinations.
Number of ARV pills per day (coded as 0, 1)
We derived the number of ARV pills per day given at ART start by dividing the number of ARV
pills given by the total number of days the pills were given.
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Cotrimoxazole Prophylaxis (coded as 0, 1)
Cotrimoxazole prophylaxis is given to all HIV positives patients irrespective of whether they
started ART or not. This is a key medication for treatment of many bacterial infections that plague
PLWH.
Table 1 below is a summary of the all variables and definitions that were used in this study.
Table 1: Measurement Matrix of the Study Variables
Measured Variable
Dependent Variables
ART Adherence
Opportunistic Infections

Aim

Definition

Aim 1
Aim 2

Survival time to death

Aim 3

Binary Outcome: 1= Adherent, 0=Less adherent
Binary category: 1 =” had an OI”, 0= otherwise”
Time from ART initiation to death/end of study
period

Independent Variables
Demographic characteristics
Policy change group

All

Year of ART Initiation

2

Health facility

All

Age
Sex
Clinical Characteristics
Weight
Had an OI at ART start

All
All

WHO Disease Stage*

All

All
2,3

Binary category: 1=Post-Policy, 0=Pre- policy
Categorical variable: 1=20 12, 2=2013, 3=2014, 4
=2015, 5=2016
Categorical variable: 1=ART Clinic 1, 2= ART Clinic
2, 3= ART Clinic 3, 4 = ART Clinic 4
Binary category: 1 =15-19, 0=20-24
Binary category: 1 =Female, 0=Male
Continuous: weight at ART initiation (in kgs)
Binary category: 1= had an OI, 0=otherwise
Categorical variable: 1 = Stage I, 2 = Stage II, 3
=Stage III & IV

Treatment Characteristics
Duration in pre-ART care
All
Binary variable: 0=<1 month, 1=1 month or more
ARV regimen
All
Binary variable: 1= TDF-based, 0=Non-TDF,
ARV Pills Per Day
1
Binary variable: 1 = 1 pill, 0 =2 pills or more
Cotrimoxazole prophylaxis
1,2
Binary variable: 1= Yes CTX, 0 = otherwise
*This classification is based on the World Health Organization (WHO) clinical staging
criteria
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Data Supervision and Management
The dissertation committee provided the overall supervision and management of the
study. The researcher supervised the data extraction exercise with the help of data specialists in
health records and staff from the participating health facilities. The data was de-identified by
generating new study IDs that were used in the analysis for all participants to ensure privacy and
confidentiality of the patients’ information. The patient clinic IDs were only used in the data
cleaning process and quality checks. The data was cleaned using STATA 15.1 and re-coded by the
researcher and a trained data manager, to create an analysis file. The abstracted data was
encrypted and stored on a password-protected computer of the researcher. The back-up dataset
was password-protected too and stored on the UTSPH server in Houston. All study records will
be disposed of as required, using the records disposal policies of Baylor-Uganda, Ministry of
Health - Uganda and UTSPH.

Data Collection
We extracted existing patient-level data from the electronic medical records databases of
the selected health facilities into a Microsoft Excel spreadsheet. The starting point of the data
extraction was the date the patient started ART. For those entered into the study cohort, we also
extracted their Pre-ART data. The data extraction was done by a trained Health Information
Technologist, using a data extraction tool (Appendix 1) and guided by the variables described in
the measurement matrix. For quality assurance, we did a reliability check using a random
selection of the patient charts. Figure 2 illustrates how the data was extracted.
39

Figure 2: Data Extraction Plan
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(N=448)

(N=3084)

Started ART between
Jan 1, 2012 – June 30, 2014
(N=1545)

The effect of early ART on
Adherence

Aim 1

Started ART between
July 1, 2014 – Dec 31, 2016
(N=1539)

Study Aims

Aim 2

The effect of early ART on Opportunistic
Infections (OIs)

Aim 3

The effect of early ART on Survival

Data for 3532 young people was extracted from the databases of one national and three regional
referral hospitals. Out of these, 448 young people did not meet the inclusion criteria and were
therefore excluded from the analysis. We extracted data on patient clinical information including
sex, age, CD4 cell count, WHO disease stage, ARV regimens, ARV pills given per day,
cotrimoxazole prophylaxis, and dates of clinic visits. Data on death, LTFU and transfer-outs was
also extracted, in addition to data on ART adherence and opportunistic infections recorded
during the follow-up clinic visits.
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Data Analysis
All statistical analyses were performed using STATA 15.1 (StataCorp LP, College Station,
TX, USA) and SAS 9.4 (SAS Institute Inc, Cary, NC, USA). We described patient baseline
characteristics using frequencies and percentages for categorical variables, and means and
standard deviation, for continuous variables. These were compared using T-tests and Pearson’s
chi-squared tests, respectively. All p-values were two-tailed and considered statistically
significant at α=0.05. To assess associations of each independent variable with the dependent
variables, univariable analyses were first performed. We conducted multivariable logistic
regression analyses to determine the effect of the change in policy on the study outcomes,
controlling for the independent variables at the start of ART. All variables that were statistically
significant at p-value <0.25 or had prior clinical significance for the outcomes from the univariable
analysis, were included in a multivariable regression model. We checked the correlation between
the variables to ensure that none was highly correlated. Possible interactions were also checked.
The variables that were included in each of the regression models are described under each aim.

Aim 1: The effect of ART guideline changes on antiretroviral adherence
All the young people who met the selection criteria were included in this analysis. We
defined the dependent variable “ART adherence” as the percent adherence for each patient
during the first 12 months of starting ART. This was coded as a binary variable, “1” if the patient
had an adherence code corresponding to ≥95% adherence and “0” otherwise. An adherence rate
of ≥95% is the threshold necessary for sustained clinical effectiveness of ART9,29,30. A young
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person was considered to be adherent if he/she had a code of “1” for all the months at 3, 6 and
12 months of follow-up. An individual was considered to be less adherent if he/she had a code of
“0” for any of the months at 3, 6 and 12 months of follow-up
The independent variable of interest was a binary time variable representing the before
and after introduction of the guidelines (pre-policy=0, post-policy=1). The pre-policy group
included young people who started ART before July 2014 (January 2012 – June 2014) and the
post-policy group included young people who started ART after July 2014 (July 2014-December
2016). The patient socio-demographic characteristics included in the regression model were
gender, age at ART initiation and health facility providing treatment. The clinical characteristics
were weight, OI at ART start (Yes, No) and WHO clinical disease stage (I, II, III &IV) at ART start.
The treatment characteristics included duration in pre-ART care (less than 1 month, 1 month or
more), ARV drug regimen (TDF, Non-TDF), the number of ARV pills per day (1 pill, 2 pills or more)
given at ART start, cotrimoxazole prophylaxis at ART start (Yes, No).
We used a multivariable Logistic regression model to examine the association between
the changes of the ART guidelines and ART adherence. We adjusted the model for the
independent variables described above. The variables were assessed at both univariable and
bivariable levels to see which factors were associated with the study outcome before fitting them
to the final multivariable model, using a p-value of <0.25 and clinical relevance. Possible
interactions or effect modifiers were also assessed. The underlying assumptions of regression
models were checked.
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Aim 2: The effect of ART guidelines changes on opportunistic infections
All the young people who met the selection criteria were included in this analysis.
The dependent variable was a disease event diagnosed during a follow-up clinic visit and
recorded in the patient’s medical record as an opportunistic infection (OI). This was coded as “1”
if the patient had an OI during the months after starting ART and “0” if the patient did not have
an OI during the months after starting ART. A young person was considered to have an OI if
he/she had a code of “1” for any of the months at 3, 6 and 12 months of follow-up. An individual
who had an OI at 3 months, was also considered to have an OI at 6 and 12 months.
The independent variable of interest was a binary time variable representing before and
after the introduction of the guidelines (pre-2014 policy =0, post-2014 policy=1). The pre-policy
group included young people who started ART before July 2014 (January 2012 – June 2014) and
the post-policy group included young people who started ART after July 2014 (July 2014December 2016). We adjusted the regression model for socio-demographic characteristics (age
at ART start, gender and ART clinic), The clinical characteristics were weight, OI at ART start (Yes,
No) and WHO clinical disease stage (I, II, III &IV) at ART start. The treatment characteristics
included duration in pre-ART care (less than 1 month, 1 month or more), ARV drug regimen (TDF,
Non-TDF), the number of ARV pills per day (1 pill, 2 pills or more) given at ART start, cotrimoxazole
prophylaxis at ART start (Yes, No) and ART adherence (adherent, less adherent) at 3, 6 and 12
months on ART.
We fit a multivariable Logistic regression model to examine the association between the
changes in the ART guidelines and occurrence of opportunistic infections. We adjusted the model
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for the independent variables described above. We run three separate models at 3 months, 6
months and 12 months to see if early initiation of ART was successful in keeping the infections
low. The variables were assessed at both univariable and bivariable levels to see which factors
were associated with the study outcome before fitting them to the final multivariable model,
using a p-value of <0.25 and clinical relevance. Possible interactions or effect modifiers were also
assessed. The underlying assumptions of regression models were checked.

Aim 3: To assess the effect of ART guidelines changes of survival and identify predictors of
Survival
Survival was defined as the time between ART initiation and death if it happened before
the end of the study period for each group. Young people who were LTFU, transferred out or
were alive at the end of the study period were censored. We restricted the follow up period to
36 months after starting ART for each cohort so as to have comparable results. For young people
who started ART before the guidelines changed, the censor date was December 2014 and for
those that started ART after the guidelines changed, the censor date was June 2016. The variable
was coded as “1” if the patient died and “0” otherwise. The independent variable of interest was
a time dummy variable representing the pre-and post-policy periods. We adjusted the regression
model for socio-demographic characteristics (age at the time of death & Gender), clinical
characteristics (weight, OI at ART start (Yes, No) and WHO clinical disease stage (I, II, III &IV) at
ART start) and treatment characteristics (duration in pre-ART care (less than 1 month, 1 month
or more), ARV drug regimen (TDF, Non-TDF), the number of ARV pills per day (1 pill, 2 pills or
44

more) given at ART start, cotrimoxazole prophylaxis at ART start (Yes, No). We tested the
difference in survival functions of both groups using the log-rank test. We fit a Cox Proportional
Hazards regression model to assess the association between ART policy changes and survival,
adjusted for the independent variables above. We generated time-to-event data, in months,
based on the date of death or end of study. Current age was derived from adding the duration
in ART care to the age at ART start and used it as a time-varying variable. The variables were
selected using a p-value of <0.25 and clinical relevance. We checked the underlying model
assumptions of the proportional hazards model using the model-based test for time by log (t)
interaction.
Human Subjects Considerations
Informed Consent/Assent was waived for this study because there was no contact with
or direct participation of patients. A waiver of consent was obtained for the charts reviewed for
quality assurance. Each study participant was assigned a de-identified unique number that was
used for analysis. The study was approved by the Makerere University School of Public Health,
Uganda National Council of Science and Technology, Baylor College of Medicine’s Institutional
Review Board, and Committee for the Protection of Human Subjects at the University of Texas
Health Sciences Center at Houston.
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JOURNAL ARTICLE 1
Effect of Antiretroviral Therapy Policy Change on ART Adherence among Young People living
with HIV in Uganda.
Abstract
Objectives: Although changes in treatment policy has led to initiation of antiretroviral therapy
(ART) before onset of advanced disease resulting in better treatment outcomes, it has
implications on long term adherence among young people. We evaluated the effect of such a
policy change on ART adherence among young people, aged 15-24 years in Uganda.
Methods: This retrospective analysis of young people living with HIV, 15-24years old, who started
ART from January 2012 – December 2016 used administrative data from the District Health
Information System (DHIS2) and the national referral hospital’s EMR. Multivariable logistic
regression was used to assess the effect of the changes in policy on ART adherence among those
who started treatment before and after the guidelines changed.
Results: ART adherence was affected by the health facility providing ART and having an
opportunistic infection at the start of ART. The policy change did not have an effect on ART
adherence. Although the percentage of adherent young people decreased at 3, 6 and 12 months,
it increased for the less adherent young people.
Conclusion: This study found that ART adherence among young people was mainly driven by
differences between health facilities providing ART and having an OI at ART start. ART adherence
declined over time. Therefore, whereas initiating treatment before onset of advanced disease is
beneficial, the implications on long term adherence cannot be overlooked.
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Introduction
The current decade has seen an exponential increase in the number of people on life
saving anti-retroviral medication1,3,33. The WHO estimates that ART has saved 11.4 million lives
worldwide over the last decade34. Despite these achievements, Uganda still has a high HIVrelated disease burden with a prevalence rate of nearly 4% among young people 15-24 years3.
There is also an increasing number of children who were prenatally infected with HIV, surviving
into adulthood17. A rise in new infections and AIDS-related deaths among this age group became
a concern among health professionals and policy makers. Within this context there were efforts
to maximize ART for HIV treatment and improve patient outcomes by revising policies to initiate
ART early in the course of the illness. With initiation at a higher CD4 count threshold, ART can
prevent the majority of these infections and deaths given the evidence it has greatly reduced
morbidity and mortality among HIV-infected individuals3-8. However, the success of ART relies
on sustaining high levels of ART adherence for viral suppression9,10.
Although high income countries adopted the “test and treat strategy” as early as the year
2000, low- and middle-income countries (LMICs) used a more gradual approach due to cost
implications and projected demands on already weak healthcare systems. Uganda adopted the
2013 ART guidelines in July 2014 and started initiating ART for all young people at CD4 cell count
≤500 cells/mm3, using a once-a day fixed-dose combination regimen. Despite increased ART
coverage, the threat posed by a higher treatment burden cannot be overlooked 15, 20,31,49,50. This
also raises medication adherence concerns in a population that has been widely reported to have
poor adherence11-15. This age group has lower ART adherence rates, mortality rates are not
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decreasing as in other age groups and there is a rise in new infections8,16. Furthermore, knowing
that early initiation means that young people are staying on ART longer than adults, it is
important to examine the implications of these policy changes on their adherence.
Few studies have examined ART adherence among young people in sub-Saharan Africa
and Uganda15,35-37. However, none of them have assessed the effect of the changes in ART policy
on adherence in this age group and the implications on future HIV programs. We therefore
assessed the effect of such a policy change on ART adherence.

Methods
Study Design and Data source
We conducted a retrospective cohort study comparing young people who started ART in
the period July 1st, 2014 to December 31st, 2016 to a historical cohort that was treated in January
1st, 2012 to 30th June 2014 before the policy change. We used administrative data from the
District Health Information System (DHIS2) and the national referral hospital’s EMR. This data,
routinely collected from patients who receive HIV treatment at the health facilities during clinic
visits, is used to plan and monitor a patient’s treatment from the date of HIV diagnosis to the
date he/she leaves the clinic either through transfer-out to another clinic, lost to follow-up (LTFU)
or death.
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Study Cohort
All individuals that were 15-24 years old at the time of ART initiation were included in the
study. We also included young people who had been diagnosed prior to or during the study
period but had not started ART. They also had at least 2 visits of follow-up data, started ART at
the selected ART clinics and were on lifelong ART. Patients who were LTFU or transferred-out
were considered for the period when they were in care. We excluded patients who were lostto- follow-up before the start of the study period, started ART for Pre-exposure prophylaxis (PrEP)
because it is short term, had no records, and had started ART elsewhere (transfer-in) for lack of
information from the referral health facility. We also excluded patients who had no follow up
visit after ART initiation.

Dependent Variable
The dependent variable “ART adherence” was defined as the percent adherence for each patient
during the first 12 months of starting ART. This was coded as a binary variable, “1” if the patient
had an ART adherence code corresponding to ≥95% adherence and “0”, otherwise. An adherence
rate of ≥95% is the threshold necessary for sustained clinical effectiveness of ART9,29,30. A young
person was considered to be adherent if he/she had a code of “1” for all the months at 3, 6 and
12 months of follow-up. An individual was considered to be less adherent if he/she had a code of
“0” for any of the months at 3, 6 and 12 months of follow-up.
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Independent Variables
The independent variable of interest was a binary time variable representing the before
and after introduction of the guidelines (pre-policy=0, post-policy=1). The pre-policy group
included young people who started ART before July 2014 (January 2012 – June 2014) and the
post-policy group included young people who started ART after July 2014 (July 2014-December
2016). The socio-demographic variables were ART clinic, gender and age at ART start. The clinical
characteristics were weight, OI at ART start (Yes, No) and WHO clinical disease stage (I, II, III &IV)
at ART start. The treatment characteristics included duration in pre-ART care (less than 1 month,
1 month or more), ARV drug regimen (TDF, Non-TDF), the number of ARV pills per day (1 pill, 2
pills or more) given at ART start, cotrimoxazole prophylaxis at ART start (Yes, No).

Analysis
All statistical analyses were performed using STATA 15. The unit of analysis was the
patient. We described and compared patient characteristics using T-tests and Pearson’s chisquared tests, respectively (Table 1). All p-values were two-tailed and considered statistically
significant at α=0.05. We examined the data to ensure that there were no sparse cells. The
duration in pre-ART care was right-skewed and we categorized it to reduce on the wide variability
between patients and have more interpretable cutoff points. To assess associations of each
independent variable with the dependent variable, ART adherence, univariable analyses were
first performed. We conducted multivariable logistic regression analyses to determine the effect
of the change in policy on ART adherence, controlling for variables at the start of ART that
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included age, sex, weight, WHO clinical disease stage, duration in pre-ART care, ARV regimen and
ARV pills per day given. All variables that were statistically significant at p-value <0.25 or had prior
clinical significance for ART adherence from the univariable analysis, were included in a
multivariable regression model. We checked the correlation between the variables to ensure that
none was highly correlated. Possible interactions were also checked and none of them was
significant. We report the unadjusted and adjusted odds ratios, and 95% confidence intervals in
Table 3.

IRB approval
The study was approved by the Makerere University School of Public Health, Uganda
National Council of Science and Technology, Baylor College of Medicine’s Institutional Review
Board, and Committee for the Protection of Human Subjects at the University of Texas Health
Sciences Center at Houston.

Results
Out of a total of 3532 young people who were initiated on ART in the study period across
the four study sites, 448 did not meet the inclusion-exclusion criteria and were excluded from
this analysis. Of the remaining 3084 patients, 50.1% started ART before and 49.9% started ART
after the policy change. In both groups, young people were more likely to be female and of older
age (20-24 years). They were less likely to have an OI at the start of treatment, but the percentage
was higher in the pre-policy group (23.54%) compared to the post-policy group (18.60%).
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Although young people were more likely to be disease stage I or II at ART stage, the post-policy
group had a bigger percentage of stage I and less stage II patients compared to the pre-policy
group. The group differences were significant. Concerning treatment characteristics, starting
treatment in less than a month of testing HIV positive was observed in both groups. However,
the post-group had more numbers (93.17%) compared to the pre-group (88.23). On further
analysis, 43.54% in the post-group started ART the same day they tested HIV positive compared
to 29.12% in the pre-group. Post-policy young people were more likely to be given a TDF-based
regimen (93%), one pill a day (86%) compared to the pre-policy group (66% & 45%, respectively).
The pre-policy group was also more likely to be given non-TDF regimen (34.35%) and 2 or more
pills per day (54.66%) compared to the post-group (7.41% & 14.43%, respectively).
Regarding our study outcome, we found that although overall more than 80% of young
people were adherent at 3, 6 and 12 months of follow-up, we observed a gradual decline in
both groups over time (Figures 3 & 4). There were no significant group differences at any of
time points.
In both the unadjusted and adjusted models, the policy did not have an effect on ART
adherence (Table 3). Age at ART start, WHO disease stage and the number of ARV pills per day
were only statistically significant in the unadjusted models at all three time points. Gender did
not have an effect on ART adherence, as were weight at ART start, and cotrimoxazole prophylaxis
in all models. Younger age (15-19 years) was only significant in the unadjusted model and was
associated with being less adherent. In the adjusted model, only the ART clinic providing the
treatment had an effect on ART adherence at 3, 6 and 12 months on ART. In both the unadjusted
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and adjusted model, young people in clinics 2, 3, and 4 more likely to be adherent compared to
the young people receiving treatment in ART clinic 1. Also, after controlling for the independent
variables in the model, young people who had an OI at ART start were more likely to be adherent
compared to young people who did not have an OI at ART start, at 6 months (AOR 1.60, 95% CI:
1.16, 2.21) and 12 months (AOR 1.34, 95% CI: 1.01, 1.77) on ART. This result was statistically
significant. Young people who had disease stage II, III and IV disease had lesser odds of being
adherent compared to those with stage I at ART start. The odds reduced as severity of disease
increased. Young people who were in pre-ART care for more than one month had a very
significant effect on ART adherence only in the unadjusted models, similar to young people who
were given one ARV pill per day.
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Table 2: Descriptive Statistics of Young People who started ART before and after the Policy
Change

Characteristic

Pre-2014 policy

Post-2014 policy

1546

1538

Dependent Variable
ART Adherence
3 months
Adherent
Less Adherent

89.11%
10.89%

88.46%
11.54%

6 months
Adherent
Less Adherent

85.98%
14.02%

84.80%
15.20%

12 months
Adherent
Less Adherent

82.21%
17.79%

79.43%
20.57%

Total

Independent Variables
Policy change group
Pre-Policy
Post- Policy

50.13%
49.87%

Year of ART initiation
2012 (reference)
2013
2014
2015
2016
Socio-Demographic Characteristics
Age at ART start in years (%)
15-19
20-24

28.78%
47.54%
23.67%

Gender (%)
Male
Female
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27.57%
36.74%
35.70%

28.91%
71.09%

28.67%
71.33%

14.81%
85.19%

13.72%
86.23%

Characteristic

Pre-2014 policy

Post-2014 policy

1546
55.26(10.15)

1538
55.45(9.30)

15.46% *
39.72% *
10.93% *
33.89% *

16.64% *
31.99% *
10.14% *
41.22% *

23.54% *
76.46% *

18.60% *
81.40% *

57.32% *
32.25% *
10.43% *

75.36%*
17.30% *
7.34% *

88.23% *
11.77% *

93.17% *
6.38% *

ARV regimen given at ART start (%)
TDF
Non-TDF

65.65% *
34.35% *

92.59% *
7.41% *

ARV pills per day at ART start (%)
1 pill
2 pills or more

45.34% *
54.66% *

85.57% *
14.43% *

97.67% *
2.33% *

99.09% *
0.91% *

Total
Weight at ART start in kgs (mean, SD)
Health Facility (%)
ART clinic 1
ART clinic 2
ART clinic 3
ART clinic 4
Clinical Characteristics
Had an OI at ART Start (%)
Yes
No
WHO disease stage at ART start (%)
Stage I
Stage II
Stage III & IV
Treatment Characteristics
Duration in Pre –ART care in months (%)
<1 month
1 month +

Cotrimoxazole Prophylaxis at ART start (%)
Yes
No (reference)
*Significant at P<0.05
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Figure 3: Trends of Adherent Young by Year of ART Initiation, before and after Policy Change
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Figure 4: Trends of Less Adherent Young by Year of ART Initiation, before and after Policy
Change
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Table 3: The Effect of the Independent Variables on ART Adherence among Young People before and after the Policy Change
3 months after ART start
Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

6 months after ART start
Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

12 months after ART start
Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Policy Change Group
Pre/Post Group
Pre-2014 policy

Reference

Reference

Reference

Reference

Reference

Reference

Post-2014 policy

0.95 (0.74, 1.21)

0.99 (0.73, 1.35)

0.92 (0.75, 1.14)

0.95 (0.73, 1.25)

0.84 (0.70, 1.02)

0.84 (0.66, 1.07)

Patient socio-demographic characteristics
Age at Art start (years)
15-19

0.53 (0.41, 0.68) **

1.13 (0.83, 1.55)

0.57 (0.46, 0.71) **

1.13 (0.85, 1.50)

0.61 (0.50, 0.74) **

1.12 (0.87, 1.45)

20-24

Reference

Reference

Reference

Reference

Reference

Reference

0.94 (0.67, 1.31)

1.11 (0.75, 1.64)

0.93 (0.69, 1.24)

1.09 (0.77, 1.55)

0.99 (0.76, 1.29)

1.18 (0.86, 1.63)

Reference

Reference

Reference

Reference

Reference

Reference

ART Clinic 1

Reference

Reference

Reference

Reference

Reference

Reference

ART Clinic 2

16.66 11.42, 24.31) **

21.98 (13.58, 35.59) **

16.48 (11.82, 22.99) **

22.67 (14.65. 35.07) **

16.81 (12.47, 22.67) **

25.23 (16.73, 38.03) **

ART Clinic 3

4.84 (3.02, 7.78) **

6.27 (3.50, 11.22) **

4.74 (3.19, 7.03) **

6.42 (3.89, 10.62) **

4.13 (2.94, 5.80) **

5.53 (3.53, 8.67) **

ART Clinic 4

11.37 (8.14, 15.87) **

14.25 (9.24, 21.97) **

8.49 (6.44, 11.20) **

11.47 (7.80, 16.85) **

7.86 (6.11, 10.10) **

11.14 (7.72, 16.07) **

1.01 (1.00, 1.03)

1.00 (0.99, 1.02)

1.01 (1.00, 1.02)

1.00 (0.99, 1.01)

1.01 (1.00, 1.02) **

1.00 (0.99, 1.01)

Yes

1.15 (0.84, 1.56)

1.31 (0.92, 1.86)

1.25 (0.95, 1.64)

1.60 (1.16, 2.21) **

1.10 (0.87. 1.39)

1.34 (1.01, 1.77) *

No

Reference

Reference

Reference

Reference

Reference

Reference

Stage I

Reference

Reference

Reference

Reference

Reference

Reference

Stage II

0.67 (0.51, 0.89) **

1.24 (0.88, 1.74)

0.71 (0.56, 0.91) **

1.21 (0.89, 1.64)

0.72 (0.58, 0.90) **

1.18 (0.89, 1.55)

Stage III & IV

0.60 (0.40, 0.90) **

0.90 (0.54, 1.50)

0.58 (0.41, 0.83) **

0.79 (0.50, 1.25)

0.60 (0.43, 0.83) **

0.76 (0.50, 1.16)

Gender
Male
Female
ART Clinic

Patient Clinical Characteristics
Weight at ART start
Had an OI at ART Start

WHO Disease Stage at ART start
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3 months after ART start
Unadjusted Model
OR (95% CI)
Patient’s Treatment Characteristics

6 months after ART start

12 months after ART start

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Reference

Reference

Reference

Reference

Reference

Reference

0.16 (0.12, 0.21) **

1.28 (0.85, 1.94)

0.17 (0.13, 0.22) **

1.31 (0.88, 1.95)

0.18 (0.14, 0.23) **

1.42 (0.95, 2.12)

0.83 (0.61, 1.13)

1.15 (0.75, 1.77)

0.87 (0.66, 1.13)

1.20 (0.82, 1.77)

0.87 (0.69, 1.10)

1.15 (0.81, 1.62)

Reference

Reference

Reference

Reference

Reference

Reference

0.77 (0.59, 1.00) *

1.03 (0.70, 1.52)

0.78 (0.62, 0.98) *

1.04 (0.73, 1.46)

0.81 (0.66, 0.99) *

1.20 (0.88, 1.63)

Reference

Reference

Reference

Reference

Reference

Reference

Duration in Pre-ART care
< 1 month
One Month or
more
ARV Regimen at ART start
TDF
Non-TDF
ARV Pills per day
1 pill
2 pills or more

Cotrimoxazole prophylaxis at ART start
Yes

0.76 (0.23, 2.51)

0.57 (0.07, 4.39)

1.06 (0.44, 2.55)

0.94 (0.27, 3.28)

0.81 (0.36, 1.84)

0.76 (0.25, 2.29)

No

Reference

Reference

Reference

Reference

Reference

Reference

*Significant at p-value 0.05
**Significant at p-value 0.01
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Discussion
This study gives an insight into the effect of 2014 ART policy change on ART adherence
among young people, ages 15-24 years in Uganda. Our study found that ART adherence declined
as the duration on ART increased. Whereas the percentage of adherent young people decreased
at 3, 6 and 12 months, it increased for the less adherent young people (Figure 3 & 4). The increase
is observed more in young people who initiated ART in 2015 and 2016. This could be attributed
to inadequate preparation of young people for ART especially in the post-policy period where the
duration between HIV diagnosis and ART initiation was reduced. Our study had more than 40%
young people that started ART the same day they were diagnosed with HIV and could have
contributed to this result. Given that the success of HIV care is dependent on the patient’s right
and willingness to accept or defer treatment39, we can therefore argue that these young people
may not have grasped the implications of the lifelong ART whose success depends on maintaining
high levels of adherence to keep the viral load low. Our findings are similar to other studies that
have reported poor ART adherence among relatively healthier patients starting ART early 40,41,42.
We also know that one’s attitude and perceptions have an effect on health behavior 43. Some may
not realize the importance of daily medication since they do not feel sick and some may still have
the belief that starting ART is a death sentence as has been reported elsewhere25,26. Therefore,
health professionals need to emphasize the importance of adhering to the daily medication and
the benefits of ART when initiating treatment in young people.
Contrary to expectation, in our study the policy change did not have an effect on ART
adherence. However, we found the ART clinic providing treatment was the main driver of ART
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adherence at 3, 6 and 12 months. In the Donabedian model, structure is defined as “the
conditions under which care is provided, including material resources, human resources, and
organizational characteristics”42. In order to provide quality HIV treatment, adequate physical
and human resources have to be available. Given that there was variability in how adherence is
measured, staffing levels, infrastructure and location of the ART clinics involved in the study,
though not the focus of this study, this may have influenced our results. In our study ART
adherence differs by health facility and therefore more research is needed to identify those
factors contributing to this result.
We also found that having an OI at ART start had an effect on ART adherence at 6 and 12
months, after adjusting for other variables in the model. Young people who had an OI at ART
start had 60% and 34% higher odds of being adherent at 6 and 12 months on ART compared to
young people who did not have an OI at ART start. Although having an OI at ART start increases
the chances of complications that are common during the first months on ART44, the desire to be
healthier and stronger may be the motivation to adhere to treatment.
This study had a number of strengths. To our knowledge this is the first study to evaluate
the effect of changes in ART policy on ART adherence among young people in Uganda. We had a
large study cohort of young people from 4 large volume HIV clinics that are representative of the
4 geographical regions in Uganda. The different regions capture the regional variation and
therefore increase generalizability of the study results. Our results must however be interpreted
in light of several limitations. We did not capture socio-demographic data on education and
marital status which may or may not have yielded different results given younger age was
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associated with being in school and the older young people were more likely to be married. The
variability in adherence measurement may have limited our ability to provide more generalizable
results. Despite the limitations the study results are still generalizable to high volume health
facilities in Uganda.

Conclusion
This study found that ART adherence among young people was mainly driven by
differences between health facilities providing ART in Uganda and whether an individual had an
OI at ART start. Although our study did not find an effect between policy change and ART
adherence, young people starting ART much earlier will lead to a higher treatment burden, and
this might negatively impact ART adherence over time. Therefore, whereas initiating treatment
before onset of advanced disease is beneficial, the implications on long term adherence cannot
be overlooked. We believe that there are factors influencing adherence that are not captured by
our study, that need further investigation.
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JOURNAL ARTICLE 2
The Effect of Changes in Antiretroviral Therapy Policy on Opportunistic Infections among Young
People living with HIV in Uganda.
Abstract
Objectives: For optimal benefits of life-saving antiretroviral therapy (ART) for people living with
the Human Immunodeficiency Virus (HIV), the ART eligibility criterion has continually been
revised to start treatment before advanced disease stages. We evaluated the effect of the
changes in the ART policy on opportunistic infections among young people, aged 15-24 years.
Methods: This was a retrospective analysis of young people living with HIV, 15-24years old, who
started ART from January 2012 – December 2016. This study used administrative data from the
District Health Information System (DHIS2) and the national referral hospital. We compared
young people who started ART before and after the policy change and assessed the effect of that
change on opportunistic infections, using multivariable logistic regression.
Results: On average, young people who started ART after the policy change had lesser odds of
having an OI compared to those who started ART before the policy at 3, 6 and 12 months on ART.
Age, the health facility, weight, and WHO disease stage were also associated with having OIs, as
well as duration in pre-ART care, ARV regimen and number of pills per day. Cotrimoxazole
prophylaxis did not have an effect on OIs.
Conclusion: Post-Policy young people were less likely to have OIs compared those who started
ART before the policy change. OIs declined over time. The positive trend is attributable to early
ART initiation, with less advanced disease, in addition to the use of more potent ARVs. However,
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there are still OIs that persist among PLWH and further research will help identify them and
design interventions to mitigate the problem.

Introduction
Despite the introduction of life-saving antiretroviral therapy (ART) for treatment and
prevention of the Human Immunodeficiency Virus (HIV), it continues to be a public health threat
in sub-Saharan Africa. In Uganda, the 4% prevalence rate among young people, the increase in
new infections and number of children who were perinatally infected with HIV becoming
adolescents and adults, is a concern for health professionals and policy makers3. AIDS-related
mortality is still high and opportunistic infections (OI) are still a major cause of death among those
whose treatment is not keeping their viral load low enough to fight off infections. Between 2005
and 2012, the number of deaths among this age group increased by 50% whereas overall it had
decreased by 30%48. It is within this context that efforts were made to maximize the benefits of
ART by revising policies to initiate treatment before the onset of advanced disease. With initiation
at a higher CD4 count threshold, ART can prevent the majority of these infections and deaths 3-8.
The WHO estimates that ART has saved 11.4 million lives worldwide over the last decade34.
Whereas high income countries started initiating ART for all people living with HIV/AIDS
immediately after diagnosis, as early as the year 2000, it was not the case for low- and middleincome countries (LMICs). LMICs adopted a more gradual approach to the test and treat strategy
considering cost and demands it would place on already weak healthcare systems. In July 2014,
Uganda adopted the 2013 ART guidelines. All young people were initiated on ART at CD4 cell
69

count ≤500 cells/mm3 regardless of clinical disease stage, using once-a day fixed-dose
combination regimens. Despite the increased ART coverage, the threat posed by a higher
treatment burden in addition to poor adherence cannot be overlooked. Opportunistic infections
still exist among young people and these negatively affect their quality of life and increase the
risk of death15,31,34,49,50
Although several studies have assessed the OIs, they focused more on infants, children
and adults and less on young people. In addition, OIs vary by region and age. Providing countryspecific data will help define local priorities, reduce barriers to, and improve treatment
outcomes. We therefore evaluated the effect of the changes in the 2014 ART policy on
opportunistic infections among young people, aged 15-24 years in Uganda.

Methods
Study Design and Data Source
For this retrospective cohort study, we used administrative data from the District Health
Information System (DHIS2) and the national referral hospital’s EMR. We compared young
people who started ART in the period July 1st, 2014 to December 31st, 2016 to a cohort that was
treated in January 1st, 2012 to 30th June 2014 before the policy change. This data, routinely
collected from patients who receive HIV treatment at the ART clinics during routine visits, is used
to monitor a patient’s treatment from the date of HIV diagnosis to the date he/she leaves the
clinic either through transfer-out to another clinic, lost to follow-up (LTFU) or death.
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Study Cohort
We included all individuals that were 15-24 years old at the time of ART initiation. Young
people diagnosed prior to or during the study period but had not started ART, were also included
in the study. Those who had at least 2 visits of follow-up data, started ART at the selected ART
clinics and were on lifelong ART were included. Young people who were LTFU or transfer-out
during the study period were included because they contributed time until the event happened.
However, we excluded patients who were lost- to- follow-up before the start of the study period
and those on Pre-exposure prophylaxis (PrEP) because it is short term. Individuals with no
records, and had started ART elsewhere were excluded because of lack of information from the
referral clinic. Patients who had no follow-up visit after ART initiation were also excluded.

Dependent Variable
We defined the dependent variable “opportunistic infection” as a disease event diagnosed during
a clinic visit and recorded in the patient’s medical record as an OI. This was coded as a binary
variable, “1” if the patient had an OI during the months after starting ART and “0” otherwise. A
young person was considered to have an OI if he/she had a code of “1” for any of the months at
3, 6 and 12 months of follow-up. An individual who had an OI at 3 months, was also considered
to have an OI at 6 and 12 months.
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Independent Variables
One of the independent variables of interest was a binary time variable (pre-2014 policy =0, post2014 policy=1). The other independent variable of interest was the year of ART initiation (2012,
2013, 2014, 2015, 2016). The pre-policy group included young people who started ART from
January 2012 – June 2014 and the post-policy group included those who started ART from July
2014-December 2016. The socio-demographic variables were ART clinic, gender and age at ART
start. The clinical characteristics were weight, OI at ART start (Yes, No) and WHO clinical disease
stage (I, II, III&IV) at ART start. The treatment characteristics included duration in pre-ART care
(less than 1 month, 1 month or more), ARV drug regimen (TDF, Non-TDF), the number of ARV
pills per day (1 pill, 2 pills or more) given at ART start, cotrimoxazole prophylaxis at ART start (Yes,
No) and ART adherence (adherent, less adherent) during the follow-up time after starting ART.

Analysis
All statistical analyses were performed using STATA 15. We described and compared patient
characteristics using T-tests and Pearson’s chi-squared tests, respectively (Table 4). All p-values
were two-tailed and considered statistically significant at α=0.05. To assess associations of each
independent variable with the dependent variable, opportunistic infection, univariable analyses
were first performed. We conducted multivariable logistic regression analyses to determine the
effect of the change in policy on opportunistic infections, controlling for all the independent
variables mentioned above. All variables that were statistically significant at p-value <0.25 or had
prior clinical significance for OIs from the univariable analysis, were included in the multivariable
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regression models. We checked the correlation between the variables to ensure that none was
highly correlated. Possible interactions were also checked and none of them was significant. We
run three separate regression models at 3 months, 6 months and 12 months to see if the change
in policy was successful in keeping the infections low. We report the unadjusted and adjusted
odds ratios, and 95% confidence intervals in Table 2.

IRB approval
The study was approved by the Makerere University School of Public Health, Uganda
National Council of Science and Technology, Baylor College of Medicine’s Institutional Review
Board, and Committee for the Protection of Human Subjects at the University of Texas Health
Sciences Center at Houston.

Results
This analysis included data from 3084 young people who met the inclusion-exclusion
criteria out of 3532. 50.13% of these started ART before and 49.87% started ART after the policy
change. Although there were no significant group differences in age at ART start and gender,
young people were more likely to be older (20-24 years) and female. The number of young people
initiating ART was different between clinics, but within the clinics there was not much difference,
pre- and post- policy. More than 76% of young people did not have an OI at ART initiation in both
groups. But among those who had an OI, the pre-policy group was bigger (23.54%) compared to
18.60% in the post-policy group. 57% pre-policy and 75% post-policy young people started ART
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with stage I disease. The pre-policy group had more young people (32%) starting ART with stage
II disease compared to post-policy group (17%). In both groups, ART initiation was in less than a
month of testing HIV positive. However, the post-policy group had a bigger percentage (93%)
compared to the pre-policy group (88%). A sub-analysis showed that among those who started
ART in less than a month, nearly 50% in the post-group and 30% in the pre-group started ART the
same day they tested positive for HIV. More young people in the pre-policy group (11.77%)
stayed in pre-ART care more than a month. Post-policy young people were more likely to be given
a TDF-based regimen (93%) and one pill a day (86%). Almost all the young people in both groups
were given cotrimoxazole prophylaxis at ART start.
With regards to our study outcome, there were significant group differences between
young people who had an OI at 3, 6 and 12 months after starting ART. The percentage of young
people with OIs declined especially after the policy changed in 2014 (Figure 5).
Starting ART pre-policy or post-post was significantly associated with having an OI at all
three time points, in the unadjusted models at 3 and 6 months on ART and in both the unadjusted
and adjusted models at 12 months on ART. Post-policy young people had less odds of having an
OI after starting ART and these odds continued to decline over time (Table 5 and 6). Younger age
(15-19 years) was associated with lesser odds of having an OI in all the three unadjusted models.
But the odds did not change over time. Male young people had higher odds of having an OI in
the unadjusted models. There were significant differences between the ART clinics providing
treatment. Young people who received treatment at ART clinic 3 had lesser odds of OIs and those
at clinics 2 and 4 had higher odds of OIs compared to those in clinic 1. Having an OI at ART start
74

increased the odds of having one after ART initiation in all 6 models. WHO disease stage was
significant in all the models and at all the time points. Young people with disease stage II, III and
IV at ART start had higher odds of having an OI compared to young people with stage I, and the
odds declined over time. Young people who started ART a month or more after being diagnosed
with HIV, had higher odds of having an OI compared to those with a shorter duration in pre-ART.
Whereas ARV regimen and the number of pills per day given at ART start had an effect on OIs,
cotrimoxazole prophylaxis did not.
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Table 4: Descriptive Statistics of Young People who started ART before and after the Policy
Change
Characteristic
Total
Dependent Variable
Had on OI
3 months
Yes
No
6 months
Yes
No
12 months
Yes
No
Independent Variables
Policy change group
Pre-Policy
Post- Policy
Year of ART initiation
2012 (reference)
2013
2014
2015
2016
Socio-Demographic Characteristics
Age at ART start in years (%)
15-19
20-24
Gender (%)
Male
Female

Pre-2014 policy

Post-2014 policy

1546

1538

48.05%
51.95%

35.84%
64.16%

54.02%
45.98%

40.54%
59.46%

60.77%
39.23%

44.97%
55.03%

50.13%
49.87%
28.78%
47.54%
23.67%

Weight at ART start in kgs (mean, SD)
Health Facility (%)
ART clinic 1
ART clinic 2
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27.57%
36.74%
35.70%

28.91%
71.09%

28.67%
71.33%

14.81%
85.19%

13.72%
86.23%

55.26(10.15)

55.45(9.30)

15.46% *
39.72% *

16.64% *
31.99% *

Characteristic
Total
ART clinic 3
ART clinic 4
Clinical Characteristics
Had an OI at ART Start (%)
Yes
No
WHO disease stage at ART start (%)
Stage I
Stage II
Stage III & IV
Treatment Characteristics
Duration in Pre –ART care in months (%)
<1 month
1 month +
ARV regimen given at ART start (%)
TDF
Non-TDF
ARV pills per day at ART start (%)
1 pill
2 pills or more
Cotrimoxazole Prophylaxis at ART start (%)
Yes
No (reference)
ART Adherence at 3 months
Adherent
Less Adherent
ART Adherence at 6 months
Adherent
Less Adherent
ART Adherence at 12 months
Adherent
Less Adherent
*Significant at P<0.05
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Pre-2014 policy

Post-2014 policy

1546
10.93% *
33.89% *

1538
10.14% *
41.22% *

23.54% *
76.46% *

18.60% *
81.40% *

57.32% *
32.25% *
10.43% *

75.36%*
17.30% *
7.34% *

88.23% *
11.77% *

93.17% *
6.38% *

65.65% *
34.35% *

92.59% *
7.41% *

45.34% *
54.66% *

85.57% *
14.43% *

97.67% *
2.33% *

99.09% *
0.91% *

89.11%
10.89%

88.46%
11.54%

85.98%
14.02%

84.80%
15.20%

82.21%
17.79%

79.43%
20.57%

Figure 5: Trends in Percentage of Young People with Opportunistic Infections at 3, 6 and 12
Months after ART Initiation
Percentage of Young Place with OIs
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Table 5: The Effect of the Independent Variables on Opportunistic Infections among HIV Positive Young People on ART, before
and after the 2014 ART Policy Change
3 months after ART start

6 months after ART start

12 months after ART start

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Pre-2014 policy

Reference

Reference

Reference

Reference

Reference

Reference

Post-2014 policy

0.60(0.52, 0.70) **

0.85 (0.70, 1.05)

0.58 (0.50. 0.67) **

0.82 (0.67, 1.00)

0.53 (0.46, 0.61) **

0.70 (0.58, 0.85) **

Policy Change Group
Pre/Post Group

Patient socio-demographic characteristics
Age at Art start (years)
15-19

0.88(0.75, 1.04)

0.77 (0.63, 0.95) *

0.88 (0.76, 1.03)

0.77 (0.63, 0.95) *

0.87 (0.74, 1.02)

0.77 (0.63, 0.93) **

20-24

Reference

Reference

Reference

Reference

Reference

Reference

1.64 (1.34, 2.01) **

1.12 (0.86, 1.47)

1.66 (0.35, 2.04) **

1.15 (0.89, 1.50)

1.55 (1.26, 1.92) **

1.10 (0.85, 1.42)

Reference

Reference

Reference

Reference

Reference

Reference

ART Clinic 1

Reference

Reference

Reference

Reference

Reference

Reference

ART Clinic 2

0.76 0.62, 0.95) **

1.18 (0.80, 1.75)

0.73 (0.59, 0.91) **

1.25 (0.86, 1.84)

0.73 (0.59, 0.91) **

1.08 (0.75, 1.56)

ART Clinic 3

0.38 (0.28, 0.52) **

0.43 (0.26, 0.70) **

0.40 (0.30, 0.54) **

0.51 (0.32, 0.81) **

0.43 (0.32, 0.58) **

0.52 (0.34, 0.82) **

ART Clinic 4

0.92 (0.75, 1.14)

1.88 (1.28, 2.78) **

0.94 (0.76, 1.16)

2.09 (1.43, 3.06) **

0.98 (0.79, 1.21)

1.81 (1.26, 2.61) **

0.97 (0.97, 0.98) **

0.99 (0.98, 1.00) *

0.97 (0.97. 0.98) **

0.99 (0.98, 1.00) *

0.98 (0.97, 0.99) **

0.99 (0.98, 1.00) *

20.92 (16.00, 27.34) **

14.70 (11.09, 19.50) **

18.13 (13.67,24.05) **

12.96 (9.63, 17.43) **

15.60 (11.59, 21.00) **

10.92 (8.01, 14.88) **

Gender
Male
Female
ART Clinic

Patient Clinical Characteristics
Weight at ART start
Had an OI at ART start
Yes
No

Reference
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3 months after ART start
Unadjusted Model
OR (95% CI)
WHO Disease Stage at ART start

6 months after ART start

12 months after ART start

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Reference

Reference

Reference

Reference

Reference

Reference

Stage II

2.63 (2.21, 3.14) **

2.08 (1.65, 2.62) **

2.42 (2.03, 2.88) **

1.80 (1.44, 2.25) **

2.35 (1.97, 2.81) **

1.71 (1.37, 2.14) **

Stage III & IV

7.68 (5.59, 10.55) **

4.27 (2.88, 6.34) **

7.36 (5.25, 10.33) **

3.97 (2.65, 5.96) **

6.25 (4.40, 8.88) **

3.32 (2.20, 5.02) **

Reference

Reference

Reference

Reference

Reference

Reference

1.60 (1.25, 2.05) **

1.75 (1.12, 2.74) *

1.76 (1.37, 2.26) **

2.21 (1.42. 3.44) **

1.68 (1.30. 2.16) **

1.78 (1.16, 2.74) **

0.45(0.38, 0.54) **

0.73 (0.56, 0.97) *

0.46 (0.38, 0.55) **

0.73 (0.55. 0.95) *

0.43 (0.36, 0.52) **

0.67 (0.51, 0.88) **

Reference

Reference

Reference

Reference

Reference

Reference

0.52 (0.44, 0.60) **

0.63 (0.49, 0.81) **

0.52 (0.45. 0.61) **

0.64 (0.50. 0.81) **

0.52 (0.45. 0.61) **

0.70 (0.55, 0.90) **

Reference

Reference

Reference

Reference

Reference

Reference

Stage I

Patient’s Treatment Characteristics
Duration in Pre-ART care
< 1 month
One Month or
more
ARV Regimen at ART start
TDF
Non-TDF
ARV Pills per day
1 pill
2 pills or more

Cotrimoxazole prophylaxis at ART start
Yes

0.88 (0.50, 1.56)

0.79 (0.33, 1.89)

0.66 (0.38, 1.17)

0.53 (0.23, 1.22)

0.70 (0.39, 1.25)

0.65 (0.28, 1.50)

No

Reference

Reference

Reference

Reference

Reference

Reference

*Significant at p-value 0.05
**Significant at p-value 0.01
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Table 6: The Effect of Year of ART Initiation on Opportunistic Infections among HIV Positive Young People on ART
3 months after ART start

6 months after ART start

12 months after ART start

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

2012

Reference

Reference

Reference

Reference

Reference

Reference

2013

0.32 (0.25, 0.41) **

0.41 (0.30, 0.57) **

0.32 (0.25, 0.41) **

0.45 (0.33, 0.61) **

0.37 90.29, 0.49) **

0.54 (0.39, 0.74) **

2014

0.44 (0.35, 0.56) **

0.62 (0.45, 0.85) **

0.43 (0.34, 0.56) **

0.67 (0.49, 0.92) *

0.43 (0.33, 0.56) **

0.65, (0.47, 0.90) **

2015

0.29 (0.22, 0.37) **

0.48 (0.34, 0.68) **

0.28 (0.22, 0.37) **

0.50, (0.35, 0.71) **

0.27 (0.21, 0.35) **

0.44 (0.31, 0.63) **

2016

0.19 (0.15, 0.25) **

0.28 (0.19, 0.41) **

0.17 (0.13, 0.22) **

0.25 (0.17, 0.36) **

0.16 (0.12, 0.22) **

0.24 (0.17, 0.35) **

Year of ART Initiation

Patient socio-demographic characteristics
Age at Art start (years)
15-19

0.88(0.75, 1.04)

0.77 (0.63, 0.96) *

0.88 (0.76, 1.03)

0.77 90.63, 0.95) *

0.87 (0.74, 1.02)

0.77 (0.63, 0.94) **

20-24

Reference

Reference

Reference

Reference

Reference

Reference

1.64 (1.34, 2.01) **

1.10 (0.84, 1.44)

1.66 (1.35, 2.04) **

1.14 (0.88, 1.49)

1.55 (1.26, 1.92) **

1.09 (0.84, 1.42)

Reference

Reference

Reference

Reference

Reference

Reference

ART Clinic 1

Reference

Reference

Reference

Reference

Reference

Reference

ART Clinic 2

0.76 0.62, 0.95) **

1.07 (0.72, 1.59)

0.73 (0.59, 0.91) **

1.10 (0.75, 1.63)

0.73 (0.59, 0.91) **

0.94 (0.64, 1.36)

ART Clinic 3

0.38 (0.28, 0.52) **

0.38 (0.23, 0.63) **

0.40 (0.30, 0.54) **

0.45 (0.28, 0.72) **

0.43 (0.32, 0.58) **

0.45 (0.29, 0.71) **

ART Clinic 4

0.92 (0.75, 1.14)

1.68 91.13, 2.50) **

0.94 (0.76, 1.16)

1.84 (1.25, 2.72) **

0.98 (0.79, 1.21)

1.58 (1.09, 2.30) *

0.97 (0.97, 0.98) **

0.99 (0.98, 1.00) **

0.97 (0.97. 0.98) **

0.99 (0.98, 1.00) *

0.98 (0.97, 0.99) **

0.99 (0.98, 1.00)

Yes

20.92 (16.00, 27.34) **

14.81 (11.14, 19.70) **

18.13 (13.67,24.05) **

13.12 (9.72, 17.73) **

15.60 (11.59, 21.00) **

10.94 (8.00, 14.96) **

No

Reference

Reference

Reference

Reference

Reference

Reference

Gender
Male
Female
ART Clinic

Patient Clinical Characteristics
Weight at ART start
Had an OI at ART start
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3 months after ART start
Unadjusted Model
OR (95% CI)
WHO Disease Stage at ART start

6 months after ART start

12 months after ART start

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Unadjusted Model
OR (95% CI)

Adjusted Model
OR (95% CI)

Reference

Reference

Reference

Reference

Reference

Reference

Stage II

2.63 (2.21, 3.14) **

1.99 (1.58, 2.52) **

2.42 (2.03, 2.88) **

1.73 (1.37, 2.18) **

2.35 (1.97, 2.81) **

1.65 (1.31, 2.07) **

Stage III & IV

7.68 (5.59, 10.55) **

3.84 (2.58, 5.73) **

7.36 (5.25, 10.33) **

3.57 (2.36, 5.38) **

6.25 (4.40, 8.88) **

3.01 (1.98, 4.57) **

Reference

Reference

Reference

Reference

Reference

Reference

1.60 (1.25, 2.05) **

1.43 (0.91. 2.25)

1.76 (1.37, 2.26) **

1.79 (1.14, 2.80)*

1.68 (1.30. 2.16) **

1.46 (0.94, 2.26)

0.45(0.38, 0.54) **

0.77 (0.58, 1.02)

0.46 (0.38, 0.55) **

0.75 (0.57, 0.99) *

0.43 (0.36, 0.52) **

0.69 (0.52, 0.91) **

Reference

Reference

Reference

Reference

Reference

Reference

0.52 (0.44, 0.60) **

0.75 (0.58, 0.97) *

0.52 (0.45. 0.61) **

0.76 (0.59, 0.97) *

0.52 (0.45. 0.61) **

0.83 (0.65, 1.06)

Reference

Reference

Reference

Reference

Reference

Reference

Stage I

Patient’s Treatment Characteristics
Duration in Pre-ART care
< 1 month
One Month or
more
ARV Regimen at ART start
TDF
Non-TDF
ARV Pills per day
1 pill
2 pills or more

Cotrimoxazole prophylaxis at ART start
Yes

0.88 (0.50, 1.56)

0.94 (0.38, 2.31)

0.66 (0.38, 1.17)

0.60 (0.25, 1.42)

0.70 (0.39, 1.25)

0.73 (0.31, 1.73)

No

Reference

Reference

Reference

Reference

Reference

Reference

*Significant at p-value 0.05
**Significant at p-value 0.01
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Discussion
In this study, our findings show that young people who started ART after the 2014 ART
policy change were less likely to have OIs compared to those who started ART before the
policy change, at all three time points (Table 5 & 6). The percentage of young people with
OIs declined over time by year of ART initiation, as more young people were started on ART
(Figure 5). Although the percentage declined between 2012 and 2013, there was an increase
between 2013 and 2014. However, after 2014, a gradual decline is observed. This positive
trend could be attributed to early ART initiation, with less advanced disease, which was
consistent with the policy change, in addition to the use of more potent ARVs. In our study,
young people were started on ART as soon as they are diagnosed with HIV to reduce the risk
of infections and this could be the reason for the decline over time in OIs and the lesser odds
of having one in the post-policy group. It is evident in the literature that the risk of getting an
OI after starting ART are very low unless the patient is not adherent to medication51. Our
results are not different from other studies done in Uganda and elsewhere in sub-Saharan
Africa31,52. A systematic review of the literature found that the risk for all OIs in LMICs
reduced to <2% during the first year on ART31. But they also noted that OIs still persist in
PLWH even with ART, similar to what was reported elsewhere20,50,53. The fact that OIs still
persist among PLWH could be the reason for the higher and increasing odds of having an OI
in the pre-policy group. Our findings also show that OIs are still a burden for young people
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living with HIV and more effort is needed to fully reap the benefits of ART in reducing such
infections. It should be noted that our study did not disaggregate the OIs and therefore does
not show the ones that have persisted in the study population.
Secondly, male young people were more likely to have OIs after ART initiation
compared to female young people in the adjusted model and at all three time points. This is
not surprising given that males have been found to be less adherent to ART and therefore at
increased risk of getting OIs after starting ART. Poor adherence, a major determinant of
treatment failure increases the risk for OIs27. This finding could be also be attributed to the
gender differences in the prevalence of some OIs like tuberculosis with the men
disproportionately affected compared to females as has been reported in the literature51.
Furthermore, the ART clinic providing the ART treatment had a significant association
with having an OI after ART initiation. Whereas young people who got their ART at clinic 3
had lesser odds of OIs, those who got their ART at clinic 4 had higher odds of OIs compared
to young people at clinic 1. Health facility-based factors and the variation in the regional
endemicity of certain OIs could be the contributing factor to this result. Though our study did
not disaggregate OIs, our results are in line with findings by Rubaihayo et. al. (2016) who
found that TB was endemic to the northern and eastern regions of the country compared to
other geographical areas because of socio-economic disparities.
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Our results also show that WHO disease stage at ART start was significantly associated
with OI occurrence. Young people with stage II, III and IV disease were more likely to have an
OI compared to those who had stage I disease. Although our study had a large number of
young people who started ART with stage 1 disease in both groups, the decreasing odds of
OIs for these advanced disease stages implies that the treatment is succeeding in reducing
the infections over time. It is also not surprising that the higher odds of having OIs especially
during the first months of treatment compared to those with less advanced disease were
observed. PLWH who start ART with more advanced disease are more likely to have
complications that are common during the first months on ART44. These start treatment with
when they are too ill and have a bigger pill burden consisting of ARVs and other drugs given
to treat opportunistic infections that are common with that disease stage. Our findings
therefore support early initiation of ART before the onset of advanced HIV disease for better
treatment outcomes on ART since it reduces morbidity and mortality among PLWHA45 .
ART regimen also had an effect on OIs. Young people who were given TDF-based
regimen had lesser odds of having an OI after ART initiation. TDF being a more potent ARV
and the recommended first line regimen7, is therefore effective in keeping the risk of OIs low.
In line with this, is the finding that young people who were given one ARV pill per day had
lesser odds of OIs. Therefore, the potency of the ARV drugs coupled with a lesser pill burden
had a positive impact on reducing opportunistic infections among young people in Uganda.
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Surprisingly cotrimoxazole prophylaxis (CTX) which is used to reduce on the risk of
bacterial infections, did not have a significant effect on the dependent variable. This may not
be surprising since CTX had been recommended for HIV-infected persons with CD4 counts
<350 cells/mm3 in resource-constrained areas 57. We were limited by the lack of CD4 count
data at ART start for all the young people in our sample. But for the few who had CD4 count
data, the mean CD4 count was >500 cells/mm3, and only 30% had <350 cells/mm3. Therefore,
CTX may not have an effect if a patient has a higher CD4 threshold and this could explain why
we did not find a significant association. This finding is very useful in light of newer policies
seeking to phase out cotrimoxazole prophylaxis among adherent PLWH.
Our study had several strengths. To our knowledge this is the first study to evaluate
the impact of the changes in the 2014 ART guidelines, on OIs among HIV-infected young
people living with HIV in Uganda. We had a large study cohort from 4 large volume ART clinics
that are geographically representative. This regional variation increases the generalizability
of the study results. This is also one of the few longitudinal studies that analyzed the effect
of policy changes on OIs. Our results had some limitations. We lacked socio-demographic
data on education and marital status. We also lacked data of CD4 count at ART initiation.
Some unobserved measures may have affected our findings as is common in observational
studies as well as some other factors that may be contributing to some of the positive trends
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in declining OIs we observed in this study. However, the study findings are still generalizable
to other high-volume HIV clinics in Uganda and useful for informing HIV interventions.

Conclusion
This study demonstrates that early ART initiation reduces morbidity due to HIV over
time. Young people who initiated ART after the policy change were less likely to have an OI
after starting treatment. However, there are still OIs that persist among PLWH and further
research will help identify them and design interventions to mitigate the problem.
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JOURNAL ARTICLE 3
The Effect of Changes in Antiretroviral Therapy Policy on survival of Young People living with
HIV in Uganda.
Abstract
Objectives: The introduction of life-saving antiretroviral therapy (ART) has prolonged the
survival of people living with HIV. Despite this, HIV continues to threaten the survival of young
people living with the virus. To mitigate this threat, the eligibility criteria was revised to start
ART early but little has been documented about the effect of these changes. We evaluated
the effect of the changes in Uganda’s ART policy on survival of young people, aged 15-24
years.
Methods: This was a retrospective analysis of young people living with HIV, 15-24years old,
who started ART between January 2012 and December 2016. This study used administrative
data from the District Health Information System (DHIS2) and the national referral. We used
multivariable Cox Proportional Hazards regression to examine the effect of the policy on
survival.
Results: There was no significant difference in the survival probabilities and the hazard ratios
of young people who started ART before and those who started ART after the policy changed.
However, although not statistically significant, the risk of death among the post-policy group
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was increased in the adjusted model. WHO disease stage, weight at ART start and ART
adherence at the time of death had an effect on survival.
Conclusion: Young people had higher survival probabilities after ART initiation regardless of
whether they started ART before or after the policy change. However, given that the risk of
death among the post-policy group was higher and ART adherence had an effect on survival,
more investigation is needed to identify factors influencing this.

Introduction
The introduction of life-saving antiretroviral therapy (ART) for treatment and
prevention of the Human Immunodeficiency Virus (HIV) has saved lives and improved survival
of people living with the virus (PLWH)23,58. The WHO estimates that ART has saved 11.4 million
lives worldwide over the last decade34. Despite these achievements, HIV continues to be a
public health threat in sub-Saharan Africa especially among young people. In Uganda, the
HIV prevalence rate among young people is 4%. There has also been an increase in new
infections. AIDS-related mortality is still high and opportunistic infections (OI) are still a major
cause of death among those whose treatment is not keeping their viral load low enough to
fight off infections. Between 2005 and 2012, the number of deaths among this age group
increased by 50% whereas overall it had decreased by 30%48. It is within this context that
efforts were made to maximize the benefits of ART for HIV treatment by revising policies to
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initiate treatment early in the course of the illness. With initiation at a higher CD4 count
threshold, ART can prevent the majority of these infections and deaths 3-8.
Although high income countries adopted the “test and treat strategy” as early as the
year 2000, low- and middle-income countries (LMICs) used a more gradual approach due to
cost implications and projected demands on already weak healthcare systems. Uganda
adopted the 2013 ART guidelines in July 2014 and started initiating ART for all young people
at CD4 cell count ≤500 cells/mm3, using a once-a day fixed-dose combination regimen.
Despite increased ART coverage, patients still die when started on ART and the threat posed
by a higher treatment burden cannot be overlooked15, 20,31,49,50.
Several studies have examined survival among PLWH, but very few have focused on
young people. In addition, little is known about the effect of the changing ART policy on
survival of young people in Uganda. Survival rates vary by region and age, and providing
country-specific data will help define local priorities and reduce barriers to treatment. We
therefore evaluated the effect of the 2014 policy ART changes on survival among young
people, aged 15-24 years, initiating ART in Uganda.
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Methods
Study Design and Data Source
We conducted a retrospective cohort study using administrative data from the District
Health Information System (DHIS2) and the national referral hospital’s EMR. We compared
young people who started ART in the period July 1st, 2014 to December 31st, 2016 to a
historical cohort that was treated in January 1st, 2012 to 30th June 2014 before the policy
change. This data, routinely collected from patients who receive HIV treatment at the ART
clinics during routine visits, is used to track a patient’s treatment plan from the date of HIV
diagnosis to the date he/she leaves the clinic either through transfer-out to another clinic,
lost to follow-up (LTFU) or death.

Study Cohort
All individuals that were 15-24 years old at the time of ART initiation and on long-term
ART, were included in the study. Patients who were LTFU or transferred-out were considered
for the period when they were in care. We excluded patients who were lost- to- follow-up
before the start of the study period, started ART for Pre-exposure prophylaxis (PrEP) because
it is short term, had no records, and had started ART elsewhere (transfer-in) for lack of
information from the referral health facility. We also excluded patients who had no follow up
visit after ART initiation.
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Dependent Variables
We defined survival as the time between ART initiation and death or end of study
period. For more comparable results the total follow-up time for each group was restricted
to 36 months after starting ART. For young people in the pre-policy group, the censor date
was December 2014 and for those in the post-policy group, the censor date was June 2017.
Length of time was measured in months. The variable was coded as “1” if the patient died
and “0” otherwise.

Independent Variables
The independent variable of interest was a binary time variable (pre-2014 policy =0,
post-2014 policy=1). The pre-policy group included young people who started ART before July
2014 (January 2012 – June 2014) and the post-policy group included young people who
started ART after July 2014 (July 2014-December 2016). The socio-demographic variables
were ART clinic, gender and age at ART start. The clinical characteristics were weight, OI at
ART start (Yes, No) and WHO clinical disease stage (I, II, III) at ART start. The treatment
characteristics included duration in pre-ART care (less than 1 month, 1 month or more), ARV
drug regimen (TDF, Non-TDF), the number of ARV pills per day (1 pill, 2 pills or more) given at
ART start, cotrimoxazole prophylaxis at ART start (Yes, No) and ART adherence (adherent, less
adherent) at the time of death/end of study period.
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Analysis
All statistical analyses were performed using STATA 15 and SAS 9.4. We described and
compared patient characteristics using T-tests and Pearson’s chi-squared tests, respectively
(Table 1). All p-values were two-tailed and considered statistically significant at α=0.05. To
assess associations of each independent variable with the dependent variable, survival,
univariable analyses were first performed. We conducted multivariable Cox Proportional
Hazards regression analyses to determine the effect of the change in policy on survival,
controlling for age at the time of the event, sex, OI at ART start, ARV regimen, ARV pills per
day given and adherence at the time of death/send of study. All variables that were
statistically significant at p-value <0.25 or had prior clinical significance for survival from the
univariable analysis, were included in the multivariable regression model. We checked the
correlation between the variables to ensure that none was highly correlated. Possible
interactions were also checked and none of them was significant. We used the log-rank test
to test the difference in survival functions between the two groups. We checked the
underlying model assumptions of the proportional hazards model using the model-based test
for time by log (t) interaction. The overall model fit was assessed using Cox-Snell residuals.
We report both unadjusted and adjusted hazard ratios and 95% confidence intervals in Table
8.
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IRB approval
The study was approved by the Makerere University School of Public Health, Uganda
National Council of Science and Technology, Baylor College of Medicine’s Institutional Review
Board, and Committee for the Protection of Human Subjects at the University Of Texas Health
Sciences Center at Houston.

Results
This analysis included data from 3084 young people who met the inclusion-exclusion
criteria out of 3532. 50.13% of these started ART before and 49.87% started ART after the
policy change. Although there were no significant group differences in age at ART start and
gender, young people were more likely to be older (20-24 years) and female. The number of
young people initiating ART was different between clinics, but within the clinics there was not
much difference, pre- and post- policy. More than 76% of young people did not have an OI at
ART initiation in both groups. But among those who had an OI, the pre-policy group was
bigger (23.54%) compared to 18.60% in the post-policy group. 57% pre-policy and 75% postpolicy young people started ART with stage I disease. The pre-policy group had more young
people (32%) starting ART with stage II disease compared to post-policy group (17%). In both
groups, ART initiation was in less than a month of testing HIV positive. However, the postpolicy group had a bigger percentage (93%) compared to the pre-policy group (88%). A sub98

analysis showed that among those who started ART in less than a month, nearly 50% in the
post-group and 30% in the pre-group started ART the same day they tested positive for HIV.
More young people in the pre-policy group (11.77%) stayed in pre-ART care more than a
month. Post-policy young people were more likely to be given a TDF-based regimen (93%)
and one pill a day (86%). Almost all the young people in both groups were given cotrimoxazole
prophylaxis at ART start. There were no group differences in the number of young people
who died during the study period. However, those in the post-policy group were more likely
to be LTFU (7.11%) or to transfer-out to another facility (19.32%) compared to those in the
pre-policy group.
The survival probabilities of both groups were close to 1 (Figure 7). The log rank test
(2.56) was not statistically significant (P <0.11) and there was not enough evidence to reject
the null hypothesis that there is no difference in the survival probabilities of the two groups.
In the both the unadjusted and adjusted models there was no significant difference
between the hazard ratios of young people who started ART before and those who started
ART after the policy changed (Table 8). However, whereas the risk of death was lower in the
unadjusted model (HR: 0.58, 95%CI: 0.29, 1.15), it was three times higher in the adjusted
model (HR: 1.55, 95%CI: 0.46, 5.28), after controlling for age at the time of death/end of study
period, gender, weight at ART start, OI at ART start, WHO disease stage at ART start, duration
in pre-ART care, number of ARV pills per day and ART adherence at the time of death/end of
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study period. Only weight at ART start, WHO disease stage and ART adherence at the time of
death/end of study period had a significant effect of survival in the adjusted regression
model. Young people who had stage II, III&IV at ART start had more than three times the risk
of death (HR 3.88, 95%CI 1.01, 14.99 and 8.63, 95%CI: 2.48, 29.98, respectively) compared to
those who had stage I at ART start. But the 95% CIs were wide. Those who were less adherent
had lower odds of survival compared to those who were adherent. The difference was
statistically significant.
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Table 7: Descriptive Statistics of Young People who started ART before and after the
Policy Change
Characteristic
Total
Dependent Variable
Deaths
Yes
No
Independent Variables
Policy change group
Pre-Policy
Post- Policy
Year of ART initiation
2012 (reference)
2013
2014
2015
2016
Socio-Demographic Characteristics
Age at ART start in years (%)
15-19
20-24
Gender (%)
Male
Female

Pre-2014 policy

Post-2014 policy

1546

1538

1.42%
98.58%

0.85%
99.15%

50.13%
49.87%
28.78%
47.54%
23.67%

Weight at ART start in kgs (mean, SD)
Health Facility (%)
ART clinic 1
ART clinic 2
ART clinic 3
ART clinic 4
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27.57%
36.74%
35.70%

28.91%
71.09%

28.67%
71.33%

14.81%
85.19%

13.72%
86.23%

55.26(10.15)

55.45(9.30)

15.46% *
39.72% *
10.93% *
33.89% *

16.64% *
31.99% *
10.14% *
41.22% *

Characteristic
Total
Clinical Characteristics
Had an OI at ART Start (%)
Yes
No
WHO disease stage at ART start (%)
Stage I
Stage II
Stage III & IV
Treatment Characteristics
Duration in Pre –ART care in months (%)
<1 month
1 month +
ARV regimen given at ART start (%)
TDF
Non-TDF
ARV pills per day at ART start (%)
1 pill
2 pills or more
Cotrimoxazole Prophylaxis at ART start (%)
Yes
No (reference)
Lost to Follow-up
Yes
No
Transfer-Out
Yes
No
Age at time of death/censor
15-19
20-24
ART Adherence at time of death/censor
Adherent
Less Adherent
*Significant at P<0.05
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Pre-2014 policy

Post-2014 policy

1546

1538

23.54% *
76.46% *

18.60% *
81.40% *

57.32% *
32.25% *
10.43% *

75.36%*
17.30% *
7.34% *

88.23% *
11.77% *

93.17% *
6.38% *

65.65% *
34.35% *

92.59% *
7.41% *

45.34% *
54.66% *

85.57% *
14.43% *

97.67% *
2.33% *

99.09% *
0.91% *

2.72*
97.28*

7.22*
92.78*

8.02*
91.98*

19.25*
80.75*

83.89% *
16.11% *

87.26% *
12.74% *

71.82%
28.18%

71.05%
28.95%

Figure 6: Trends in Deaths among Young People before and after the Policy Change

Percentage of Deaths
Percentage

2
1.5
1
0.5
0
2012

2013

2014

2015

2016

Year of ART Initiation

Figure 7: Comparison of Survival Probabilities of Young People before and after the 2014
ART Policy
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Table 8: The Effect of the Independent Variables on Survival among HIV Positive Young
People, Before and After the 2014 ART Policy Change
Characteristic
Pre/Post Group
Pre-2014 policy
Post-2014 policy
Patient socio-demographic characteristics
Age at time of time of death/censor
15-19 years
20-24 years
Gender
Male
Female
Patient Clinical Characteristics
Weight at ART start
Had an OI at ART start
Yes
No
WHO disease stage at ART start
Stage I
Stage II
Stage III & IV
Patient Treatment Characteristics
Duration in PreART care
< 1 month
One Month or more
ARV pills per day at ART start
1 pill
2 pills or more
Adherence at the time of death/censor
Adherent
Less adherent
*Significant at P<0.05
**Significant at P<0.01

Unadjusted HR (95% CI)

Adjusted HR (95% CI)

Reference
0.58 (0.29, 1.15)

Reference
1.55 (0.46, 5.28)

1.84 (0.83, 4.08)
Reference

1.45 (0.49, 4.26)
Reference

3.13 (1.56, 6.31) **
Reference

1.15 (0.36, 3.60)
Reference

0.91 (0.89, 0.93) **

0.93 (0.89, 0.97) **

3.12 (1.60, 6.07) **
Reference

0.97 ((0.40, 2.33)
Reference

Reference
3.53 (1.23, 10.14) *
23.56 (9.48, 58.67) **

Reference
3.88 (1.01, 14.99) *
8.63 (2.48, 29.98) **

Reference
0.30 (0.04, 2.14)

Reference
0.60 (0.08, 4.37)

0.36 (0.19, 0.71) **
Reference

0.41 (0.11, 1.47)
Reference

Reference
0.46 (0.16, 1.32)

Reference
0.26 (0.09, 0.80) *
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Discussion
In this study we found that young people had higher survival probabilities after ART
initiation regardless of whether they started ART before or after the policy change (Figure 7).
Less than 2% (0.54 per 1000 person-months) died during the follow-up period which was
lower than the 6.2 per 100 person years reported in a similar study done in Uganda59. Our
sample had a very small number of deaths. The low number of deaths could be attributed to
the increased ART coverage in the country that is prolonging the life of PLWHA given the
strong and consistent evidence that ART improves survival23,24.
This study did not find a significant association between the policy change group and
survival of young people. With the small number of deaths in our sample, we may not have
had an adequate number of deaths to detect a difference between the groups. Although the
result was not significant, it was surprising that the risk of death increased in the post-policy
group in the adjusted model. Whereas in the unadjusted model, the post-policy group had a
lower hazard rate (HR: 0.58, 95%CI: 0.29, 1.15) compared to the pre-policy group, this
changed (HR: 1.55, 95%CI: 0.46, 5.28) in favor of the pre-policy group in the adjusted model.
It should also be noted that a bigger number of young people in the post-policy group had
disease stage I at ART start and started ART in less than a month of being diagnosed.
Therefore, there may by other factors driving this increased risk that need further research.
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In addition, our study was limited by the lack of death registry data and a centralized
database for PLWHA. There are unreported deaths in the community in general and also
among young people who are lost or were transferred-out to other ART clinics for treatment.
Therefore, this study could have underestimated death and overestimated survival.
It is evident in published literature that disease severity significantly increases the risk
of death61 among PLWH. Our study found that young people with disease stage II, III & IV at
ART start had a significant effect on survival (HR 3.88, 95%CI 1.01, 14.99 and 8.63, 95%CI:
2.48, 29.98, respectively). Young people had more than three times the risk of death and
nearly nine times higher risk compared to those with stage I at ART start, during the 36
months of follow-up. Other studies done in Africa have reported similar results that OIs and
the Immune Reconstitution Inflammatory Syndrome (IRIS) were major causes of death after
initiation of ART61,62. Our results could be attributed to the number of young people in our
sample who had disease stage III and IV at the start of treatment. Overall nearly 40% of the
young people had disease stage II, III & IV at ART start. In addition, 23% of that young people
in the pre-policy group and 18% in the post-policy group had an OI at the start of ART. It
should also be noted that although the prevalence of OIs is not as high as before the ART era,
they still exist and there are some that still persist50,52 . Therefore, their impact on survival
cannot be overlooked or underestimated.
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Our study also found that ART adherence at the time of death/study period had a
significant effect on survival. It was surprising that less adherent young people had a lower
hazard ratio compared to the adherent young people (HR:0.26, 95%CI: 0.09, 0.80). This was
contrary to what we expected to find and what has been reported in published literature.
Several studies have found that less adherent patients had a higher risk of death compared
to adherent patients. Studies in Ethiopia, found that the risk of death was nearly 3 times
higher (HR: 2.9695, 95% CI: 1.396 – 5.203) among patients with poor adherence63. In Uganda
it has been reported that non-adherent patients were 2 times more likely to die compared to
adherent patients64. Therefore, given that unexpected results, the existing literature, and the
low number of deaths in the study sample, more investigation is needed into the survival of
young people starting ART in the post policy era.
Among the strengths of this study is that this is the first study to evaluate the effect
of the changes in ART policy on survival among young people in Uganda. This study had a
large study cohort of young people from 4 large volume HIV clinics that are representative of
the 4 geographical regions in Uganda. The regional variation increases generalizability of the
study results. Our study also had some limitations. Our study may have misclassified the
number of young people who were LTFU and transferred out as dead due to lack of tracking
such patients. Adolescents who were perinatally infected with HIV may have introduced some
survival bias in our analysis. Also common in such studies, some unobserved measures may
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exist and could have affected our findings. However, our findings are unlikely to differ from
other ART clinics in Uganda.

Conclusion
In conclusion therefore, young people are likely to survive longer after ART initiation
regardless of whether they started ART before or after the policy changed. However, given
that the risk of death among the post-policy group was higher and ART adherence had an
effect on survival, more investigation is needed to identify factors that may be influencing
this.
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CONCLUSION
This study found that ART adherence among young people was mainly driven by
differences between health facilities providing ART in Uganda and whether an individual had
an OI at ART start and not by policy change. Also, ART adherence declined over time. This
study also found that the risk of OIs was lower among young who initiated ART after the policy
change. Furthermore, young people are more likely to survive longer after ART initiation
regardless of whether they started ART before or after the policy changed. Therefore,
whereas initiating treatment before onset of advanced disease is beneficial to reducing HIVrelated morbidity and mortality, the implications on long term adherence cannot be
overlooked. Given our findings, we believe that there are factors influencing ART adherence,
OIs and survival among young people that are not captured by our study, that need further
investigation.
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APPENDICES
Appendix 1: Data extraction tool
Qn.

Description
Information

1.

Name of Health Facility

2.

Patient Name

3.

Patient Clinic Number

4.

Patient Study ID

Response
1=ART Clinic 1; 2= ART Clinic 2; 3 = ART Clinic 3; 4=
ART Clinic 4
Will only be used for data extraction and cleaning.
A unique study ID will be generated for analysis
Will only be used for data extraction and cleaning.
A unique study ID will be generated for analysis
This is the ID that will be used in the analysis

Demographic and Baseline Information
5.

Sex

0=Male 1=Female

6.

Date of Birth

dd/mm/yyyy

7.

In years

9.

Age
Date Patient started treatment at this
health facility
Date patient was diagnosed with HIV

10.

ART start date

dd/mm/yyyy

11.

13.

ART regimen at ART start
Number of pills in a daily dose at ART
start
Weight at ART start

in kilograms

14.

WHO clinic disease stage at ART start

1=Stage 1; 2=Stage 2; 3=Stage 3; 4=Stage 4

15.

TB status at ART start

1=No signs; 2=suspect; 3 =TB Rx

16.

New/Other OIs at ART start

1 =Yes, 0=No

17.

Name of new/other OIs at ART start

18.

CD4 cell count at ART start

Cells/mm3

19.

Pre-ART Opportunistic Infection (OI)

1 =Yes, 0=No

20.

Cotrimoxazole (CPT) dose at ART start

1 =Yes, 0=No

21.

Duration in Pre-ART care

In months

8.

12.

dd/mm/yyyy
dd/mm/yyyy
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22.

Followup information – Repeat for every visit for the specified study duration
Visit date
dd/mm/yyyy

23.

Follow-up date

dd/mm/yyyy

24.

TB status

1=No signs; 2=suspect; 3 =TB Rx

25.

1 =Yes, 0=No

26.

New/Other OIs at ART start
Name of new/other OIs

27.

WHO clinical disease stage

1=Stage 1; 2=Stage 2; 3=Stage 3; 4=Stage 4

28.

ARV adherence score

1=Adherent (≥ 95%), 0=Less Adherent (<95%)

29.

Transfer out date

dd/mm/yyyy

30.

Loss to follow up date

dd/mm/yyyy

31.

Date patient died

dd/mm/yyyy
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Appendix 3: Research Approval – Baylor College of Medicine

117

Appendix 4: Research Approval – UNCST

118

Appendix 5: Human Subjects Certification – CITI certificate

119

REFERENCES

1. Uganda Bureau Of Statistics. The National Population And Housing Census 2014 – Main
Report. . 2016.

2. Government Of Uganda, ICAP At Columbia University. Uganda Population-Based HIV
Impact Assessment UPHIA 2016–2017. . September 2017.

3. Uganda AIDS Commission. Country Progess Report 2016. . 2016.

4. UNAIDS. UNAIDS Data. Http://AIDSinfo.UNAIDS.Org. Accessed February 2, 2018.

5. World Health Organization. Consolidated Guidelines On The Use Of Antiretroviral Drugs
For Treating And Preventing HIV Infection: Recommendations For A Public Health Approach.
World Health Organization; 2016.

6. World Health Organization. HIV And Adolescents: Guidance For HIV Testing And
Counselling And Care For Adolescents Living With HIV: Recommendations For A Public
Health Approach And Considerations For Policy-Makers And Managers. . 2013.

7. World Health Organization. March 2014 Supplement To The 2013 Consolidated
Guidelines On The Use Of Antiretroviral Drugs For Treating And Preventing HIV Infection:
Recommendations For A Public Health Approach. . 2014.
120

8. Montaner JSG, Lima VD, Harrigan Pr, Et al. Expansion Of HAART Coverage Is Associated
With Sustained Decreases In HIV/AIDS Morbidity, Mortality And HIV Transmission: The "HIV
Treatment As Prevention" Experience In A Canadian Setting. Plos One [Electronic Resource].
2014;9(2):E87872.

9. Granich R, Gupta S, Hersh B, Et al. Trends In AIDS Deaths, New Infections And Art
Coverage In The Top 30 Countries With The Highest AIDS Mortality Burden; 1990-2013. Plos
One [Electronic Resource]. 2015;10(7):E0131353.

10. Granich R, Kahn JG, Bennett R, Et al. Expanding Art For Treatment And Prevention Of
HIV In South Africa: Estimated Cost And Cost-Effectiveness 2011-2050. Plos One.
2012;7(2):E30216.

11. Insight Start Study Group. Initiation Of Antiretroviral Therapy In Early Asymptomatic HIV
Infection. N Engl J Med. 2015;2015(373):795-807.

12. Yang E, Mphele S, Moshashane N, Et al. Distinctive Barriers To Antiretroviral Therapy
Adherence Among Non-Adherent Adolescents Living With HIV In Botswana. AIDS Care.
2017:1-8.

121

13. Kim SH, Gerver SM, Fidler S, Ward H. Adherence To Antiretroviral Therapy In
Adolescents Living With HIV: Systematic Review And Meta-Analysis. AIDS.
2014;28(13):1945-1956.

14. Nachega JB, Hislop M, Nguyen H, Et al. Antiretroviral Therapy Adherence, Virologic And
Immunologic Outcomes In Adolescents Compared With Adults In Southern Africa. J Acquir
Immune Defic Syndr. 2009;51(1):65-71.

15. Adedinsewo Da, Wei Sc, Robertson M, Et al. Timing Of Antiretroviral Therapy Initiation
In A Nationally Representative Sample Of HIV-Infected Adults Receiving Medical Care In The
United States. AIDS Patient Care STDs 2014;28(12):613-621.

16. Mugavero MI, Amico Kr, Westfall AO, Et al. Early Retention In HIV Care And Viral Load
Suppression: Implications For A Test And Treat Approach To HIV Prevention. J Acquir
Immune Defic Syndr. 2012;59(1):86-93.

17. World Health Organization. Antiretroviral Drugs For Treating Pregnant Women And
Preventing HIV Infection In Infants: Recommendations For A Public Health Approach-2010
Version. World Health Organization; 2010.

18. Stricker SM, Fox Ka, Baggaley R, Et al. Retention In Care And Adherence To Art Are
Critical Elements Of HIV Care Interventions. AIDS And Behavior. 2014;18(5):465-475.
122

19. Anoje C, Agu Ka, Oladele EA, Et al. Adherence To On-Time Art Drug Pick-Up And Its
Association With Cd4 Changes And Clinical Outcomes Amongst HIV Infected Adults On FirstLine Antiretroviral Therapy In Nigerian Hospitals. AIDS Behav. 2017;21(2):386-392.

20. Mills EJ, Nachega JB, Buchan I, Et al. Adherence To Antiretroviral Therapy In Sub-Saharan
Africa And North America: A Meta-Analysis. Jama. 2006;296(6):679-690.

21. Gulick Rm. Antiretroviral Treatment 2010: Progress And Controversies. J Acquir Immune
Defic Syndr. 2010;55 Suppl 1:S43-8.

22. Elbirt D, Asher I, Mahlev-Guri K, Et al. Direct Monthly Highly Active Antiretroviral
Therapy Supply - A Method To Increase Patient's Adherence And Outcome. Experience Of
One AIDS Centre In Israel. Int J Std AIDS. 2014;25(8):579-586.

23. Buregyeya E, Naigino R, Mukose A, Et al. Facilitators And Barriers To Uptake And
Adherence To Lifelong Antiretroviral Therapy Among HIV Infected Pregnant Women In
Uganda: A Qualitative Study. BMC Pregnancy Childbirth. 2017;17(1):94-017-1276-X.

24. Mekuria La, Prins JM, Yalew Aw, Sprangers Ma, Nieuwkerk Pt. Sub-Optimal Adherence
To Combination Anti-Retroviral Therapy And Its Associated Factors According To SelfReport, Clinician-Recorded And Pharmacy-Refill Assessment Methods Among HIV-Infected
Adults In Addis Ababa. AIDS Care. 2017;29(4):428-435.
123

25. Okoboi S, Ssali L, Yansaneh Ai, et al. Factors Associated With Long-Term Antiretroviral
Therapy Attrition Among Adolescents In Rural Uganda: A Retrospective Study. J Int AIDS Soc.
2016;19(5 Suppl 4):20841.

26. Williams Pl, Storm D, Montepiedra G, et al. Predictors Of Adherence To Antiretroviral
Medications In Children And Adolescents With HIV Infection. Pediatrics. 2006;118(6):E174557.

27. Damtie D, Yismaw G, Woldeyohannes D, Anagaw B. Common Opportunistic Infections
And Their Cd4 Cell Correlates Among HIV-Infected Patients Attending At Antiretroviral
Therapy Clinic Of Gondar University Hospital, Northwest Ethiopia. BMC Res Notes.
2013;6:534-0500-6-534.

28. Iroezindu M, Ofondu E, Hausler H, Van Wyk B. Prevalence And Risk Factors For
Opportunistic Infections In HIV Patients Receiving Antiretroviral Therapy In A ResourceLimited Setting In Nigeria. J AIDS Clin Res. 2013;3:002.

29. De Beaudrap P, Boulle C, Lewden C, Et al. Morbidity After Antiretroviral Therapy
Initiation In HIV-1-Infected Children In West Africa: Temporal Trends And Relation To Cd4
Count. Pediatr Infect Dis J. 2013;32(4):354-360.

124

30. Mzileni Mo, Longo-Mbenza B, Chephe Tj. Mortality And Causes Of Death In HIV-Positive
Patients Receiving Antiretroviral Therapy At Tshepang Clinic In Doctor George Mukhari
Hospital. Pol Arch Med Wewn. 2008;118(10):548-554.

31. Alemayehu M, Yisehak Y, Alaro W, Alemayehu B. Opportunistic Infections Among
HIV/AIDS Patients Taking Ante-Retroviral Therapy At Tertiary Care Hospital In Wolaita Zone,
Southern Ethiopia. . Journal Of AIDS And Clinical Research. 2017;8(665).

32. Abo Y, Zannou Djimon M, Messou E, Et al. Severe Morbidity After Antiretroviral (Art)
Initiation: Active Surveillance In HIV Care Programs, The IEDEA West Africa Collaboration.
BMC Infect Dis. 2015;15:176-015-0910-3.

33. Lawn Sd, Myer L, Orrell C, Bekker L, Wood R. Early Mortality Among Adults Accessing A
Community-Based Antiretroviral Service In South Africa: Implications For Programme
Design. AIDS. 2005;19(18):2141-2148.

34. Abaasa AM, Todd J, Ekoru K, et al. Good Adherence To HAART And Improved Survival In
A Community HIV/AIDS Treatment And Care Programme: The Experience Of The AIDS
Support Organization (TASO), Kampala, Uganda. BMC Health Services Research.
2008;8(1):241.

125

35. WHO U, UNICEF. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions In
The Health Sector. . 2009.

36. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. Cost-Effectiveness Of Antiretroviral
Regimens In The World Health Organization's Treatment Guidelines: A South African
Analysis. AIDS. 2011;25(2):211-220.

37. Braitstein P, Siika A, Hogan J, Et al. A Clinician-Nurse Model To Reduce Early Mortality
And Increase Clinic Retention Among High-Risk HIV-Infected Patients Initiating Combination
Antiretroviral Treatment. J Int AIDS Soc. 2012;15(1):7-2652-15-7.

38. Johannessen A, Naman E, Ngowi Bj, Et al. Predictors Of Mortality In HIV-Infected
Patients Starting Antiretroviral Therapy In A Rural Hospital In Tanzania. BMC Infectious
Diseases. 2008;8(1):52.

39. Sieleunou I, Souleymanou M, Schönenberger A, Menten J, Boelaert M. Determinants Of
Survival In AIDS Patients On Antiretroviral Therapy In A Rural Centre In The Far‐North
Province, Cameroon. Tropical Medicine & International Health. 2009;14(1):36-43.

40. Mageda K, Leyna GH, Mmbaga EJ High Initial HIV/AIDS-Related Mortality And-Its
Predictors Among Patients On Antiretroviral Therapy In The Kagera Region Of Tanzania: A
Five-Year Retrospective Cohort Study. AIDS Research And Treatment. 2012;2012.
126

41. Ayele W, Mulugeta A, Desta A, Rabito Fa. Treatment Outcomes And Their Determinants
In HIV Patients On Anti-Retroviral Treatment Program In Selected Health Facilities Of
Kembata And Hadiya Zones, Southern Nations, Nationalities And Peoples Region, Ethiopia.
BMC Public Health. 2015;15:826-015-2176-5.

42. Donabedian A, Bashshur R. An Introduction To Quality Assurance In Health Care. Oxford;
New York: Oxford University Press; 2003.

43. Begley Ce, Lairson D, Morgan Ro, Rowan PJ, Balkrishnan R. Evaluating The Healthcare
System: Effectiveness, Efficiency, And Equity. Health Administration Press; 2013.

44. Andersen Rm. Revisiting The Behavioral Model And Access To Medical Care: Does It
Matter? J Health Soc Behav. 1995;36(1):1-10.

45. Centers For Disease Control And Prevention. Understanding The HIV Care Continuum.
Centers For Disease Control And Prevention: Atlanta, Ga, USA 2016:1-4.

46. Yehia Br, Stephens-Shields Aj, Fleishman Ja, Et al. The HIV Care Continuum: Changes
Over Time In Retention In Care And Viral Suppression. Plos One. 2015;10(6):E0129376.

47. Lester Rt, Mills EJ, Kariri A, Et al. The HAART Cell Phone Adherence Trial (Weltel Kenya1):
A Randomized Controlled Trial Protocol. Trials. 2009;10(1):87.
127

48. Wools-Kaloustian K, Kimaiyo S, Diero L, Et al. Viability And Effectiveness Of Large-Scale
HIV Treatment Initiatives In Sub-Saharan Africa: Experience From Western Kenya. AIDS.
2006;20(1):41-48.

49. Weinhardt Ls, Carey MP, Johnson BT, Bickham NL. Effects Of HIV Counseling And Testing
On Sexual Risk Behavior: A Meta-Analytic Review Of Published Research, 1985-1997. Am J
Public Health. 1999;89(9):1397-1405.

50. Kahana Sy, Rohan J, Allison S, Frazier Tw, Drotar D. A Meta-Analysis Of Adherence To
Antiretroviral Therapy And Virologic Responses In HIV-Infected Children, Adolescents, And
Young Adults. AIDS And Behavior. 2013;17(1):41-60.

51. Rubaihayo J, Tumwesigye Nm, Konde-Lule J, Wamani H, Nakku-Joloba E, Makumbi F.
Frequency And Distribution Patterns Of Opportunistic Infections Associated With HIV/AIDS
In Uganda. BMC Research Notes. 2016;9(1):501.

52. Hirnschall G, Harries Ad, Easterbrook PJ, Doherty Mc, Ball A. The Next Generation Of The
World Health Organization's Global Antiretroviral Guidance. Journal Of The International
AIDS Society. 2013;16(1):18757.

53. Uganda A. Indicator Survey 2011. Demographic And Health Surveys, ICF International.
2012.
128

54. Government Of Uganda, Icap At Columbia University. Uganda Population-Based HIV
Impact Assessment Uphia 2016–2017. . 2017.
55. Grinsztejn B, Hosseinipour Mc, Ribaudo Hj, Et al. Effects Of Early Versus Delayed
Initiation Of Antiretroviral Treatment On Clinical Outcomes Of HIV-1 Infection: Results
From The Phase 3 Hptn 052 Randomised Controlled Trial. The Lancet Infectious Diseases.
2014;14(4):281-290.
56. Drouin O, Bartlett G, Nguyen Q, Et al. Incidence And Prevalence Of Opportunistic And
Other Infections And The Impact Of Antiretroviral Therapy Among HIV-Infected Children
In Low-And Middle-Income Countries: A Systematic Review And Meta-Analysis. Clinical
Infectious Diseases. 2016;62(12):1586-1594.
57. Montaner Js, Lima Vd, Barrios R, Et al. Association Of Highly Active Antiretroviral
Therapy Coverage, Population Viral Load, And Yearly New HIV Diagnoses In British
Columbia, Canada: A Population-Based Study. The Lancet. 2010;376(9740):532-539.
58. Mills Ej, Nachega Jb, Buchan I, Et al. Adherence To Antiretroviral Therapy In Sub-Saharan
Africa And North America: A Meta-Analysis. Jama. 2006;296(6):679-690.
59. World Health Organization. HIV And Adolescents: Guidance For HIV Testing And
Counselling And Care For Adolescents Living With HIV: Recommendations For A Public
Health Approach And Considerations For Policy-Makers And Managers. . 2013.

129

60. Paterson Dl, Swindells S, Mohr J, Et al. Adherence To Protease Inhibitor Therapy And
Outcomes In Patients With HIV Infection. Ann Intern Med. 2000;133(1):21-30.
61. Bangsberg Dr, Deeks Sg. Is Average Adherence To HIV Antiretroviral Therapy Enough? J
Gen Intern Med. 2002;17(10):812-813.
62. Mutevedzi Pc, Lessells Rj, Heller T, Barnighausen T, Cooke Gs, Newell M. Scale-Up Of A
Decentralized HIV Treatment Programme In Rural Kwazulu-Natal, South Africa: Does
Rapid Expansion Affect Patient Outcomes?/Mise En Place Elargie D'un Programme
Decentralise De Traitement Du Vih Dans Le Kwazulu-Natal Rural, Afrique Du Sud: Une
Expansion Rapide Affecte-Elle Les Resultats Des Patients?/Ampliacion De Un Programa
Descentralizado De Tratamiento Del Vih ...? Bull World Health Organ. 2010;88(8):593.
63. Yang E, Mphele S, Moshashane N, Et al. Distinctive Barriers To Antiretroviral Therapy
Adherence Among Non-Adherent Adolescents Living With HIV In Botswana. AIDS Care.
2017:1-8.
64. Ford N, Mills Ej, Egger M, Centers Id. Immunodeficiency At Start Of Art: The Persistent
Problem Of Late Presentation To Care. . 2014.
65. Newman Ce, Persson A, Miller A, Brown Rj. “Just Take Your Medicine And Everything
Will Be Fine”: Responsibilisation Narratives In Accounts Of Transitioning Young People
With HIV Into Adult Care Services In Australia. AIDS Care. 2016;28(1):131-136.

130

66. Nachega Jb, Hislop M, Nguyen H, Et al. Antiretroviral Therapy Adherence, Virologic And
Immunologic Outcomes In Adolescents Compared With Adults In Southern Africa. J
Acquir Immune Defic Syndr. 2009;51(1):65-71.
67. Bygrave H, Mtangirwa J, Ncube K, Ford N, Kranzer K, Munyaradzi D. Antiretroviral
Therapy Outcomes Among Adolescents And Youth In Rural Zimbabwe. Plos One.
2012;7(12):E52856.
68. Lowenthal Ed, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand Ra.
Perinatally Acquired HIV Infection In Adolescents From Sub-Saharan Africa: A Review Of
Emerging Challenges. The Lancet Infectious Diseases. 2014;14(7):627-639.
69. Ferrand Ra, Briggs D, Ferguson J, Et al. Viral Suppression In Adolescents On Antiretroviral
Treatment: Review Of The Literature And Critical Appraisal Of Methodological
Challenges. Tropical Medicine & International Health. 2016.
70. Brooks Jt, Kaplan Je, Holmes Kk, Benson C, Pau A, Masur H. HIV-Associated
Opportunistic Infections—Going, Going, But Not Gone: The Continued Need For
Prevention And Treatment Guidelines. Clinical Infectious Diseases. 2009;48(5):609-611.
71. Iroezindu M, Ofondu E, Hausler H, Van Wyk B. Prevalence And Risk Factors For
Opportunistic Infections In HIV Patients Receiving Antiretroviral Therapy In A ResourceLimited Setting In Nigeria. J AIDS Clin Res. 2013;3:002.

131

72. Damtie D, Yismaw G, Woldeyohannes D, Anagaw B. Common Opportunistic Infections
And Their Cd4 Cell Correlates Among HIV-Infected Patients Attending At Antiretroviral
Therapy Clinic Of Gondar University Hospital, Northwest Ethiopia. Bmc Res Notes.
2013;6:534-0500.
73. Holmes Cb, Losina E, Walensky Rp, Yazdanpanah Y, Freedberg Ka. Review Of Human
Immunodeficiency Virus Type 1-Related Opportunistic Infections In Sub-Saharan Africa.
Clinical Infectious Diseases. 2003;36(5):652-662.
74. Hogg Rs, Heath K, Bangsberg D, Et al. Intermittent Use Of Triple-Combination Therapy Is
Predictive Of Mortality At Baseline And After 1 Year Of Follow-Up. AIDS.
2002;16(7):1051-1058.
75. De Geest S, Sabate E. Adherence To Long-Term Therapies: Evidence For Action. Eur J
Cardiovasc Nurs. 2003;2(4):323.
76. Fagbami O, Oluwasanjo A, Fitzpatrick C, Fairchild R, Shin A, Donato A. Factors Supporting
And Inhibiting Adherence To HIV Medication Regimen In Women: A Qualitative Analysis
Of Patient Interviews. The Open AIDS Journal. 2015;9:45-50.
77. Curran K, Ngure K, Shell-Duncan B, Et al. 'If I Am Given Antiretrovirals I Will Think I Am
Nearing The Grave': Kenyan HIV Serodiscordant Couples' Attitudes Regarding Early
Initiation Of Antiretroviral Therapy. AIDS. 2014;28(2):227-233.

132

78. Andersen Rm. Revisiting The Behavioral Model And Access To Medical Care: Does It
Matter? J Health Soc Behav. 1995:1-10.
79. Holtzman Cw, Brady Ka, Yehia Br. Retention In Care And Medication Adherence: Current
Challenges To Antiretroviral Therapy Success. Drugs. 2015;75(5):445-454.
80. Carrieri Mp, Raffi F, Lewden C, Et al. Impact Of Early Versus Late Adherence To Highly
Active Antiretroviral Therapy On Immuno-Virological Response: A 3-Year Follow-Up
Study. Antivir Ther (Lond ). 2003;8(6):585-594.
81. Lewis M, Colbert A, Erlen J, Meyers M. A Qualitative Study Of Persons Who Are 100%
Adherent To Antiretroviral Therapy. AIDS Care. 2006;18(2):140-148.
82. Low A, Gavriilidis G, Larke N, Et al. Incidence Of Opportunistic Infections And The Impact
Of Antiretroviral Therapy Among HIV-Infected Adults In Low-And Middle-Income
Countries: A Systematic Review And Meta-Analysis. Clinical Infectious Diseases.
2016;62(12):1595-1603.
83. Williams Pl, Storm D, Montepiedra G, Et al. Predictors Of Adherence To Antiretroviral
Medications In Children And Adolescents With HIV Infection. Pediatrics.
2006;118(6):E1745-57.
84. World Health Organization. March 2014 Supplement To The 2013 Consolidated
Guidelines On The Use Of Antiretroviral Drugs For Treating And Preventing HIV
Infection: Recommendations For A Public Health Approach. . 2014.
133

85. WHO. Who Confirms Antiretroviral Therapy Reduces The Risk Of Life-Threatening HIVRelated Infections. Http://Www.Who.Int/HIV/Mediacentre/News/Incidence-Oi-ImpactArt-News/En/. Updated 2016. Accessed June 20, 2017.
86. Nabukeera-Barungi N, Elyanu P, Asire B, Et al. Adherence To Antiretroviral Therapy And
Retention In Care For Adolescents Living With HIV From 10 Districts In Uganda. Bmc
Infectious Diseases. 2015;15(1):520.
87. Mills Ej, Bakanda C, Birungi J, Et al. Life Expectancy Of Persons Receiving Combination
Antiretroviral Therapy In Low-Income Countries: A Cohort Analysis From Uganda. Ann
Intern Med. 2011;155(4):209-216.
88. Kim Sh, Gerver Sm, Fidler S, Ward H. Adherence To Antiretroviral Therapy In
Adolescents Living With HIV: Systematic Review And Meta-Analysis. AIDS.
2014;28(13):1945-1956.
89. Jain V, Byonanebye Dm, Amanyire G, Et al. Successful Antiretroviral Therapy Delivery
And Retention In Care Among Asymptomatic Individuals With High Cd4+ T-Cell Counts
Above 350 Cells/Mul In Rural Uganda. AIDS. 2014;28(15):2241-2249.
90. World Health Organization. Consolidated Guidelines On The Use Of Antiretroviral Drugs
For Treating And Preventing HIV Infection: Recommendations For A Public Health
Approach. World Health Organization; 2016.

134

91. Anoje C, Agu Ka, Oladele Ea, Et al. Adherence To On-Time Art Drug Pick-Up And Its
Association With Cd4 Changes And Clinical Outcomes Amongst HIV Infected Adults On
First-Line Antiretroviral Therapy In Nigerian Hospitals. AIDS Behav. 2017;21(2):386-392.
92. Adakun Sa, Siedner Mj, Muzoora C, Et al. Higher Baseline Cd4 Cell Count Predicts
Treatment Interruptions And Persistent Viremia In Patients Initiating Arvs In Rural
Uganda. J Acquir Immune Defic Syndr. 2013;62(3):317-321.
93. Rosen S, Fox Mp. Retention In HIV Care Between Testing And Treatment In Sub-Saharan
Africa: A Systematic Review. Plos Med. 2011;8(7):E1001056.
94. Holtzman Cw, Shea Ja, Glanz K, Et al. Mapping Patient-Identified Barriers And Facilitators
To Retention In HIV Care And Antiretroviral Therapy Adherence To Andersen's
Behavioral Model. AIDS Care. 2015;27(7):817-828.
95. Brinkhof Mwg, Boulle A, Weigel R, Et al. Mortality Of HIV-Infected Patients Starting
Antiretroviral Therapy In Sub-Saharan Africa: Comparison With HIV-Unrelated Mortality.
Plos Medicine / Public Library Of Science. 2009;6(4):E1000066.
96. Davies M, Phiri S, Wood R, Et al. Temporal Trends In The Characteristics Of Children At
Antiretroviral Therapy Initiation In Southern Africa: The Iedea-Sa Collaboration. Plos
One. 2013;8(12):E81037.
97. Initiation Of Antiretroviral Therapy In Early Asymptomatic HIV Infection. N Engl J Med.
;373(9):795-807.
135

98. Trotta Mp, Ammassari A, Melzi S, Et al. Treatment-Related Factors And Highly Active
Antiretroviral Therapy Adherence. J Acquir Immune Defic Syndr. 2002;31 Suppl 3:S12831.
99. Lamb Mr, Fayorsey R, Nuwagaba-Biribonwoha H, Et al. High Attrition Before And After
Art Initiation Among Youth (15-24 Years Of Age) Enrolled In HIV Care. AIDS.
2014;28(4):559-568.
100.

Namutebi Am, Kamya Mr, Byakika-Kibwika P. Causes And Outcome Of

Hospitalization Among HIV-Infected Adults Receiving Antiretroviral Therapy In Mulago
Hospital, Uganda. Afr Health Sci. 2013;13(4):977-985.
101.

Rubaihayo J, Tumwesigye Nm, Konde-Lule J, Wamani H, Nakku-Joloba E, Makumbi F.

Frequency And Distribution Patterns Of Opportunistic Infections Associated With
HIV/AIDS In Uganda. Bmc Research Notes. 2016;9(1):501.
102.

Guillen S, Garcia San Miguel L, Resino S, Et al. Opportunistic Infections And Organ‐

Specific Diseases In HIV‐1‐Infected Children: A Cohort Study (1990–2006). HIV Medicine.
2010;11(4):245-252.
103.

Rubaihayo J, Tumwesigye Nm, Konde-Lule J. Trends In Prevalence Of Selected

Opportunistic Infections Associated With HIV/AIDS In Uganda. Bmc Infectious Diseases.
2015;15(1):187.

136

104.

Alemayehu M, Yisehak Y, Alaro W, Alemayehu B. Opportunistic Infections Among

HIV/AIDS Patients Taking Ante-Retroviral Therapy At Tertiary Care Hospital In Wolaita
Zone, Southern Ethiopia. . Journal Of AIDS And Clinical Research. 2017;8(665).
105.

Zumla A, George A, Sharma V, Herbert Rhn, Oxley A, Oliver M. The Who 2014 Global

Tuberculosis Report—Further To Go. The Lancet Global Health. 2015;3(1):E10-E12.
106.

Mbonye M, Seeley J, Ssembajja F, Birungi J, Jaffar S. Adherence To Antiretroviral

Therapy In Jinja, Uganda: A Six-Year Follow-Up Study. Plos One. 2013;8(10):E78243.
107.

Moges N, Kassa G. Prevalence Of Opportunistic Infections And Associated Factors

Among HIV Positive Patients Taking Anti-Retroviral Therapy In Debremarkos Referral
Hospital, Northwest Ethiopia. J AIDS Clin Res. 2014;5(5):1-300.
108.

Gilks C, Vitoria M, World Health Organization. Guidelines On Co-Trimoxazole

Prophylaxis For HIV-Related Infections Among Children, Adolescents And Adults In
Resource-Limited Settings: Recommendations For A Public Health Approach. . 2006.
109.

Nachega Jb, Hislop M, Dowdy Dw, Et al. Adherence To Highly Active Antiretroviral

Therapy Assessed By Pharmacy Claims Predicts Survival In HIV-Infected South African
Adults. J Acquir Immune Defic Syndr. 2006;43(1):78-84.
110.

Bakanda C, Birungi J, Mwesigwa R, Et al. Survival Of HIV-Infected Adolescents On

Antiretroviral Therapy In Uganda: Findings From A Nationally Representative Cohort In
Uganda. Plos One. 2011;6(4):E19261.
137

111.

'Government Of Uganda', 'Uganda AIDS Commission'. The Uganda HIV And

AIDS Country Progress Report July 2015-June 2016
. . 2016.
112.

Lawn Sd, Myer L, Orrell C, Bekker L, Wood R. Early Mortality Among Adults Accessing

A Community-Based Antiretroviral Service In South Africa: Implications For Programme
Design. AIDS. 2005;19(18):2141-2148.
113.

Massavon W, Barlow-Mosha L, Mugenyi L, et al. Factors Determining Survival And

Retention Among HIV-Infected Children And Adolescents In A Community Home-Based
Care And A Facility-Based Family-Centred Approach In Kampala, Uganda: A Cohort
Study. Isrn AIDS. 2014;2014.
114.

Ayele W, Mulugeta A, Desta A, Rabito FA. Treatment Outcomes And Their

Determinants In HIV Patients On Anti-Retroviral Treatment Program In Selected Health
Facilities Of Kembata And Hadiya Zones, Southern Nations, Nationalities And Peoples
Region, Ethiopia. BMC Public Health. 2015;15:826-015.
115.

Abaasa Am, Todd J, Ekoru K, et al. Good Adherence To HAART And Improved Survival

In A Community HIV/AIDS Treatment And Care Programme: The Experience Of The AIDS
Support Organization (TASO), Kampala, Uganda. BMC Health Services Research.
2008;8(1):241

138

139

